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These studies explored interactions between flavanols and nitric oxide in order to 
investigate implications for vascular health. Study 1 investigated acute effects of flavanol 
consumption on cutaneous microvascular endothelial function in young and older 
individuals along with chronic exposure in older individuals. This was accomplished by 
assessing skin blood flow response to local heating (thermal reactivity, TR); skin was 
clamped at 34°C and 40°C and values were normalized to those attained at 43°C. Older 
individuals demonstrated an attenuated TR at baseline during the entire local heating 
phase (58.4 ± 2.5% versus 49.3 ± 2.6%, p<0.05). Acutely following flavanol ingestion 
there was a significant increase in TR (52.4 ± 2.1% versus 56.1 ± 2.0%, p=0.05) that was 
not different with age. There was no effect of chronic flavanol exposure on TR in older 
individuals; however, there was a significant decrease in mean arterial pressure (95 ± 3 
mmHg versus 91 ± 3 mmHg, p<0.001). These results contribute to research regarding 
flavanols increasing NO bioavailability; acutely via an improvement in cutaneous 
microvascular endothelial function and chronically via a reduction in blood pressure. 
Study 2 investigated the acute effects of flavanol consumption on cerebrovascular 
endothelial function in young and older individuals along with chronic flavanol exposure 
 v
in older individuals. This was accomplished by assessing basal cerebral blood flow 
indices (cerebral vascular conductance index, CVCi) and CBF response to hypercapnia 
(cerebral vasomotor reactivity; CVMR). At baseline older individuals demonstrated a 
reduced CVCi (0.85 ± 0.04 cm/s*mmHg versus 0.55 ± 0.04 cm/s*mmHg p=0.001) and 
CVMR (8.6 ± 0.6 versus 6.9 ± 0.4, p=0.05). An unexpected finding was that flavanol 
ingestion led to an acute decrease in CVCi (0.71 ± 0.04 cm/s*mmHg versus 0.62 ± 0.04 
cm/s*mmHg p<0.05) and CVMR (8.6 ± 0.6 versus 6.1 ± 0.5, p=0.001) that was not 
different with age. In older individuals, chronic exposure led to a significant increase in 
CVCi (0.60 ± 0.05 cm/s*mmHg versus 0.72 ± 0.06 cm/s*mmHg, p<0.05) but had no 
effect on CVMR. These data provide evidence for an improvement in cerebral 
hemodynamics following chronic exposure in older individuals.  
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1Chapter I: Introduction 
The number of individuals over 65 years of age increased from 34.8 million in 
2000 to 40.2 million in 2010 and is projected to be 88.5 million by 2050. Accordingly, 
this population will go from accounting for 13% of the overall population in 2010 to 20% 
of a much greater population in 2050 (212). Cardiovascular disease (CVD) is currently 
the number one cause of mortality in the US and its incidence increases significantly with 
age in both males and females (167). The term CVD includes diseases of the circulatory 
system with the main public health concerns being hypertension, heart disease, stroke, 
and peripheral artery disease. Taking into account only coronary heart disease, 
hypertension and stroke, which together account for 75% of CVD deaths, the estimated 
direct and indirect costs associated with the treatment of these diseases in 2008 was 
already about 300 billion dollars annually (167). Currently, an estimated 83 million adults 
in the US alone suffer from CVD and, though the deaths from CVD are falling, the 
number of individuals with symptoms is not following the same trend. This suggests that 
lives are being saved by the availability of new drugs and development of new 
procedures while the prevalence of the disease remains unaltered (167).  
One of the primary underlying pathologies of CVD is atherosclerosis, a disease 
process that develops sub-clinically in childhood and then presents with clinical 
symptoms such as angina, myocardial infarction, stroke or death during middle age or 
beyond. One of the initiating events in the development of atherosclerosis is endothelial 
dysfunction. Extensive research in this area has revealed that one of the most relevant 
physiological changes that occurs with aging and is the underlying cause of endothelial 
dysfunction, is a reduction in production and/or bioavailability of NO, a ubiquitous and 
potent vascular vasodilator (155, 184). However, it is important to note that this 
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progression from sub-clinical to clinical manifestations is related, not only to aging, but 
also to other modifiable, lifestyle-related risk factors. 
There is compelling evidence that environmental factors, including nutrition, are 
key to the transition from an asymptomatic process to clinical sequelae (156). A number 
of meta-analyses have supported a negative correlation between the consumption of 
plant-based foods, including fruits and vegetables, and the risk of CVD (53) and have 
even supported a dose-response (85). These positive vascular benefits are believed to be 
due to the presence of ‘bioactive’ molecules, termed polyphenols that are present in 
plant-based foods.  
Polyphenols are nonessential molecules that, by definition, are not considered 
vitamins or minerals; however, they do demonstrate disease-preventative properties. 
Flavanols, a family of polyphenols found predominantly in many fruits, green tea, red 
wine and cocoa products have been shown to confer vascular benefit. They have been 
shown to demonstrate cardio protective effects in epidemiological, observational and 
dietary intervention studies (8, 31, 56, 105). Furthermore, a number of randomized, 
placebo-controlled trials involving the ingestion of a flavanol-containing cocoa beverage 
have shown improvements in endothelial function via an increase in NO bioavailability 
(12, 67, 87, 90, 147, 180).  
As a result of this interplay between diet and vascular health, this dissertation 
investigated the acute and chronic effects of flavanol ingestion on cutaneous 
microvascular and cerebral vascular function in aging.  Investigations such as these have 
the potential to guide more precise age-related, evidence-based public health dietary 
recommendations as well as to provide preliminary insight for future mechanistic studies 
exploring novel pharmacological agents.  
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Chapter II: Statement of the Problem 
 
 The projected increase in the number of individuals over 65 years of age, their 
correlated increase in CVD risk, and the associated financial burden attest to the 
importance of developing ways to delay or prevent the onset of CVD. 
 The long subclinical progression of atherosclerosis, evidence that dietary choices 
favorably alter this progression along with data that polyphenol-rich foods provide 
vascular benefit attest to the importance of continuing with this line of  research. 
 Therefore, the overall purpose of these studies was to examine the effects of flavanol 
consumption on endothelial function and NO bioavailability in aging in order to 
explore implications for human CV health.  
Study 1 focused on investigating the acute effects of flavanol consumption on cutaneous 
microvascular function in young and older individuals and explored the same effects 
following chronic flavanol exposure in older individuals. 
Study 1 Specific Aims. To determine the acute and chronic effects of flavanol ingestion on 
cutaneous microvascular function in both young and older humans. 
Study 2 focused on investigating the acute effects of flavanol consumption on cerebral 
vascular function in young and older individuals along with the effects of chronic 
flavanol consumption on cerebral vascular function in older individuals. 
Study 2 Specific Aims. To determine the acute and chronic effects of flavanol ingestion on 
cerebral vascular function in both young and older humans. 
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Chapter III: Experimental Design 
 
In order to accomplish the aims of this dissertation, two studies utilizing a 
randomized, double-blind, placebo-controlled cross-over study design were conducted. 
These studies allowed the assessment of whether a dietary flavanol intervention could 
acutely improve endothelial function in microvascular and cerebrovascular vessels, 
presumably via an increase in NO bioavailability, in two groups: individuals over 60 
years of age and a group of younger individuals. In addition, these studies explored 
whether chronic exposure to flavanols in older individuals would have an effect on 
endothelial function in microvascular and cerebrovascular vessels, again presumably 
through enhanced basal NO bioavailability.  
The acute portion of both these investigations included young and older 
individuals and required 2 days, separated by a minimum of 3 days, as subjects received 
either a flavanol-containing drink or a placebo. All parameters were assessed pre-
ingestion and then 2 hours post-ingestion of the test drink. The chronic portions included 
a smaller cohort of older individuals. This phase was a double-blind, cross-over design 
that required that these individuals consume a test drink at home for 28 days with a 
washout period of at least two weeks between test periods. Subjects came in for testing 
prior to the first intervention and then again within 3 days of consuming their 28th 
beverage. Following the chronic intervention only fasting, baseline measures were 
assessed.  
 
Study 1. The purpose of this study was to investigate the acute and chronic effects of 
flavanol ingestion on cutaneous microvascular function in young and older individuals. 
This was accomplished by assessing skin blood flow response to a standard local heating 
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protocol (thermal reactivity, TR) as an assessment of endothelial function. We 
hypothesized the following:  
1) At baseline, older individuals would demonstrate an impaired TR compared with 
the young,  
2) Both groups would demonstrate an increase in TR two hours following flavanol 
consumption; however, the magnitude of improvement would be greater in the 
older individuals,  
3) There would be an increase in baseline TR in the older individuals following 
chronic exposure to the flavanols, and  
4) None of these effects would be seen following ingestion of the placebo. 
 
Study 2. The purpose of this study was to investigate the acute and chronic effects of 
flavanol ingestion on cerebral vascular function in young and older individuals. This was 
done by assessing cerebral blood flow response to hypercapnia (cerebral vasomotor 
reactivity, CVMR). We hypothesized the following:  
1) At baseline, older individuals would demonstrate a reduced CVMR compared 
with the young,  
2) Both groups would demonstrate an increase in CVMR two hours following 
flavanol consumption; however, the magnitude of increase would be greater in the 
older individuals,  
3) There would be an increase in baseline CVMR following chronic exposure to the 
flavanols, and  
4) None of these effects would be seen following ingestion of the placebo. 
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Chapter IV: Study #1 
Cutaneous Microvascular Response to the Acute and Chronic Ingestion of Flavanols 
in Young and Older Humans: Role of Nitric Oxide 
ABSTRACT 
Aging is associated with a progressive decline in endothelial function that 
contributes to cardiovascular disease (CVD) risk. Lifestyle choices, including nutrition, 
are known to modulate the progression of CVD. The cutaneous circulation represents an 
easily accessible microvascular bed and evidence suggests that impairments in the 
microcirculation precede overt clinical signs of disease. Therefore, this study investigated 
the effect of flavanols (~ 528 mg, provided by The Hershey Company) on cutaneous 
microvascular endothelial function with aging following both acute and chronic 
exposure. It was hypothesized that older individuals would exhibit a reduced cutaneous 
vasodilatory response to a local heating stimulus (thermal reactivity, TR) compared with 
the young at baseline, that this reduction would be acutely restored following flavanol 
ingestion and it would also be restored following chronic flavanol exposure in older 
individuals. For TR, skin blood flow (SkBF) was assessed while the skin was clamped at 
34°C and 40°C and values were normalized to a maximal value obtained during 43°C 
heating. Cutaneous vascular conductance (CVC) was calculated as the ratio of SkBF to 
mean arterial pressure (MAP).  For the acute portion of the study, 15 young (19-28 yrs) 
and 15 older (62-78 yrs) individuals were tested on two separate days; they were 
provided either a nutrient-matched placebo or a flavanol-containing test drink 
(randomized order, double-blinded) and TR was assessed pre- and 2 hours post-ingestion. 
For the chronic portion of the study, 11 older individuals (62-72 yrs) were recruited and 
TR was assessed at baseline and then following 28 days of flavanol consumption. In 
accordance with prior studies, at baseline older individuals demonstrated a reduced CVC 
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during the last 5 minutes of the stable plateau phase at 40°C (72.1 ± 2.9% versus 62.0 ± 
3.0%, p<0.05) but not 34°C (10.8 ± 0.6% versus 11.9 ±0.7%, p>0.05) compared with the 
young. Acutely following flavanol ingestion there was a significant increase in SkBF 
response when considering the entire 30 minutes of 40°C heating (52.4 ± 2.1% versus 
56.1 ± 2.0%, p=0.05) but, contrary to the hypothesis, this response did not differ between 
the young and older individuals. There was no effect of chronic flavanol ingestion on TR 
in the older individuals, either the last 5 minutes of the plateau phase or over the 30 
minutes of local heating; however, there was a significant decrease in mean arterial 
pressure (MAP, Baseline: 95 ± 3 mmHg, Flavanols: 91 ± 3 mmHg, p<0.001). This 
suggests that, though chronic exposure to flavanols did not affect TR, flavanols 
consumption was long enough to exert positive vascular effects. These results contribute 
to existing research regarding flavanols having vascular health benefit; acutely via an 
improvement in cutaneous microvascular endothelial function and chronically via a 
reduction in blood pressure. Further studies are required to elucidate underlying 
mechanisms.  
 
INTRODUCTION 
Cardiovascular disease (CVD) is the number one cause of mortality in the US and 
its incidence increases significantly with age in both males and females (167). Taking 
into account only coronary heart disease, hypertension and stroke, which together 
account for 75% of CVD deaths, the estimated direct and indirect costs associated with 
the treatment of these diseases in 2008 was about 300 billion dollars annually (167). 
Currently, an estimated 83 million adults suffer from CVD in the US alone and, though 
the deaths from CVD are falling, the number of individuals with symptoms is not 
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following the same trend. This suggests that lives are being saved by the availability of 
new drugs and development of new procedures while the prevalence of the disease 
remains unaltered (167). Aging is one of the primary risk factors for CVD. Hence, of 
considerable concern is that the number of individuals over 65 years of age is projected to 
increase from the 40.2 million in 2010 to 88.5 million by 2050. Accordingly, this 
population will go from accounting for 13% of the overall population in 2010 to 20% of a 
much greater population in 2050 (212).  
One of the principal underlying pathologies of CVD is atherosclerosis. 
Atherosclerosis is a process that develops over a lifetime; it can remain subclinical for 
many years prior to presentation of clinical symptoms including angina, myocardial 
infarction, stroke or death. The likelihood of clinical manifestations is especially 
prevalent in older individuals who have life-style associated risk factors such as 
hypertension, hypercholesterolemia, smoking, diabetes, and obesity.  
Endothelial dysfunction is believed to be the primary event in the development of 
atherosclerosis as the endothelium plays an integral role in maintaining vascular 
homeostasis. Endothelial dysfunction is associated with atherosclerotic risk factors (38, 
213) and is also a predictor of adverse CV events (80, 197). This dysfunction is due, in 
large part, to a decreased bioavailability of nitric oxide (NO) as NO mediates many of the 
protective functions exerted by a healthy endothelium. Aging is associated with reduced 
bioavailability of NO, a progressive decline in endothelial function, and increased risk of 
CVD (39, 155).  
There is compelling evidence that environmental factors, including nutrition, are 
key to the transition from an asymptomatic process to clinical manifestations of 
atherosclerosis (156). The endothelium constitutes the predominant tissue to which any 
molecule is exposed following digestion and absorption into the blood stream and thus 
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represents a potential site of action for ingested compounds. A number of meta-analyses, 
assessing numerous large scale epidemiological studies have shown that increased 
consumption of plant-based foods, including fruits and vegetables, decreases the risk of 
CVD and have even supported a dose-response (52, 53, 85).  
Current thinking is that the health benefit of plant-based foods is not due solely to 
vitamins and minerals contained in these foods, but also to the presence of bioactive 
compounds called polyphenols: small, nonessential molecules that possess disease-
preventative properties. Over the past decade flavanols, one of the more prevalent family 
of polyphenols, have become the focus of intense research. Flavanols are found in a high 
concentration in certain fruits and in foods such as cocoa products, green tea, red wine 
and soy products (154).  
Numerous studies have shown that flavanols increase NO bioavailability. This has 
been demonstrated in cultured endothelial cells and in rodents (161, 178, 193, 194) as 
well as humans (12, 67, 87, 90, 147, 180). There is evidence to suggest that the 
underlying mechanism accounting for the increase in NO bioavailability may differ 
between acute and chronic consumption of flavanols. This belief is supported by studies 
that demonstrate an increase in basal NO following chronic flavanol consumption then an 
even further increase following an acute dose of flavanols (12, 88, 180).  
Endothelium-dependent vasomotor function reflects the integrity of the 
endothelial layer and is used as a surrogate of NO bioavailability. The skin is emerging as 
an ideal site for evaluation of endothelial function as it has been suggested that the 
cutaneous microcirculation can serve as a model for generalized microvascular 
dysfunction (94, 108). Skin blood flow (SkBF) response to a standard local heating 
protocol (thermal reactivity; TR) is a common, non-invasive research technique used to 
assess cutaneous microvascular function. This response is predominantly NO-mediated 
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(106, 144) and is reduced in a variety of at-risk and diseased populations. TR is also 
reduced with aging (95, 127, 145).  
This study was designed to investigate both the acute and chronic effects of 
flavanol ingestion on TR. The acute portion of the study involved a cohort of young and 
older individuals while the chronic portion only included an older population. The 
majority of studies have demonstrated an improvement in larger arteries such as the 
brachial artery (12, 90, 147). However, whether or not endothelial function can be 
restored in the cutaneous microcirculation following flavanol ingestion remains 
unknown. We hypothesized that the older individuals would have an impaired TR 
compared with the young prior to flavanol consumption (i.e. at baseline) but TR would be 
acutely restored to the level of the young following flavanol ingestion. In addition, we 
hypothesized that this impairment would be improved following chronic flavanol 
consumption in the older individuals. 
 
METHODS 
Subjects. For the acute portion of the study, 15 young (range: 19-28 yr old; 8 men) and 15 
older individuals (range: 62-78 yr old; 7 men) were recruited to participate (see Table 2 
for subject descriptive information) and each visited the laboratory on 2 separate days 
(days 1 & 2). In order to control dietary intake of flavanols prior to testing subjects were 
asked to do the following: 1) avoid flavanol-rich foods including chocolate/cocoa 
products, green tea, red wine and most fruits in the 3 days prior to the study and 2) 
document all food intake on the day prior to their testing day so they could consume a 
similar diet prior to day 2 of testing (see Appendix A for Acute Study Instructions) (157, 
158). Subjects came into the laboratory at approximately the same time for their 2 testing 
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days following a 12 hour fast, having refrained from caffeine and exercise for 24 hours. 
None of the young women were on birth control and all were tested during the early 
follicular phase of their menstrual cycle (41). All of the older women were 
postmenopausal. All subjects were healthy, nonsmokers with no diagnosed 
cardiovascular disease. None of the younger subjects were taking medications; however, 
11 of the older subjects were taking medications, mainly for allergies, thyroid and 
cholesterol and one older female was taking hormone replacement therapy. Those 
subjects on medications refrained from taking them on the morning of each of their 
testing days.  
For the chronic portion of the study, 11 older individuals (range: 62-72 yr old; 3 
men) were recruited, 9 of whom were also part of the acute portion of the study. Subjects 
were provided with enough drink powder to consume a test drink at home for 28 days. 
They were not asked to follow any specific dietary restrictions during that time; however, 
they were asked to consume the test drink at approximately the same time each day 
(morning, afternoon or evening). They were also asked to return to the laboratory with all 
empty canisters and unused product. Subjects came in for testing within 3 days of 
consuming their 28th drink, following a 12 hour fast, having refrained from caffeine and 
exercise for 24 hours (see Appendix A for Chronic Study Instructions).  
Prior to its commencement, the consent form and study procedures were approved 
by the Institutional Review Board at the University of Texas at Austin. 
 
Instrumentation. Upon arrival in the laboratory all study procedures and risks were 
explained, questions were answered and then all participants provided informed consent. 
On each study day, height and weight were assessed using a medical–grade seca769 scale 
(seca corp., CA, USA). Subjects were then asked to lie semi-recumbent on a patient bed 
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and a fasting blood sample was drawn from the antecubital fossa for the measurement of 
glucose and lipids. Following the blood draw, subjects were instrumented with 5 
electrodes. Both cardiac rhythm and heart rate were continuously monitored throughout 
the experimental protocol from an electrocardiogram on a patient monitor (GE DASH 
4000, General Health Care). A blood pressure cuff was placed on the left arm and 
intermittent blood pressure measurements were obtained by auscultation of the brachial 
artery via electrosphygmomanometry (Tango+; SunTech, Raleigh, NC). Following a 
minimum of 20 minutes of rest, baseline heart rate and blood pressure were assessed in 
all subjects. Mean arterial blood pressure (MAP) was calculated as one-third pulse 
pressure plus diastolic blood pressure. 
Skin blood flow (SkBF) was indexed using cutaneous red blood cell flux via 
laser-doppler flowmetry. Subjects were instrumented with 2 integrating probes (MoorLab 
Laser Doppler Perfusion Monitor, Moor Instruments) inset within 2 heating elements (3-
cm diameter, Peritemp4005; Perimed) placed at 2 sites on the dorsal side of the right 
forearm. The product of average speed and concentration of moving red blood cells, 
represented by ‘flux,’ was used to represent SkBF. Skin temperature was assessed at the 
interface between the skin and the heating element using a thermocouple probe taped to 
the skin underneath one of the heating elements, randomly chosen (IT-18, Physitemp 
Instruments, Inc. New Jersey, USA). 
 
Local Heating Protocol. The manipulation of local skin temperature at these sites of 
cutaneous blood flow measurement allowed for the assessment of TR. Temperature of the 
heating elements was initially set to 34°C for 15 minutes. Local heating element 
temperature was then increased to 40°C for 30 minutes and then 43°C for a final 30 
minutes (rate of 1.0°C every 10 seconds). This rate of temperature increase and the length 
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of time for measurements have been shown to induce a cutaneous vasodilatory response 
that is primarily NO-mediated (106, 144). None of the subjects reported feeling pain in 
response to this heating protocol. This is important because feeling pain leads to a 
cutaneous vasodilatory response that is not primarily NO-mediated (106). The final 
heating stage of 43°C was chosen as it elicits a maximal vasodilatory response (106). A 
blood pressure was taken via auscultation of the brachial artery during the last 3 minutes 
of each heating stage so that cutaneous vascular conductance (CVC) could be calculated. 
CVC was calculated as the ratio of SKBF red cell flux to MAP. All testing was 
conducted in a temperature controlled room (21-24°C). 
 
Acute Effects of Flavanol Ingestion. At the end of the heating protocol, the heating 
elements were turned off and removed from the skin. They were removed to avoid 
‘desensitization’ that may occur in the skin with prolonged heating (43, 72). As this was a 
placebo-controlled, double-blinded study subjects were then provided a test drink 
(randomized order), either flavanol-containing (~528mg) or a nutrient-matched placebo, 
(see Table 1.1 for nutritional composition). Both drinks were provided by The Hershey 
Co., in powdered form so they were reconstituted by a third party with 8oz of warm, 
purified water just prior to consumption (see Appendix A for Test Drink Mixing 
Instructions). All subjects consumed the beverage within 10 minutes and a timer was 
started immediately upon completion. Subjects were asked to remain resting in the semi-
recumbent position after consuming the test drink. 
Seventy-five minutes following ingestion of the test drink, subjects were re-
instrumented with the laser-doppler probes and heating units. This timing was chosen so 
that the end of the 30 minutes at 40°C would coincide with 2 hours post ingestion of the 
test drink. Plasma flavanols and associated metabolites have been shown to peak 2 hours 
 14
following consumption (12, 87, 180). The local heating protocol was repeated as outlined 
above.  
Young male and older subjects were scheduled for their second day of testing 
after allowing for a minimum of 3 days of ‘washout’ as this length of time has been used 
in other similar studies (12, 147, 180) Young females had to wait for their menstrual 
cycle to begin the following month. For day 2 the experimental protocol was identical to 
the first study day with the only difference being that the test drink administered was the 
one not given on day 1. The drinks were given in a double-blinded and randomized 
fashion.   
Chronic Effects of Flavanol Ingestion. Subjects came in for testing within 3 days of 
consuming their 28th drink with a minimum of 2 weeks between the interventions to 
avoid potential carry over effects (88, 157). All instrumentation along with the local 
heating protocol was identical to the assessment of the acute effects of flavanol ingestion. 
However, during these study days the testing measures were done only once while the 
subject was fasted.     
    
Blood Analysis. Glucose and lipids were assayed simultaneously using the Cholestech 
LDX analyzer (Inverness Medical, Biosite Inc, CA, USA) within 30 minutes of collection 
into a heparinized vacutainer tube. This point of care analyzer has been validated against 
a hospital reference laboratory (34).  
 
Data Analysis. Analogue output signals from cardiac rhythm, heart rate, both lasers and 
the thermocouple were converted, via a data acquisition system, to a digital signal 
allowing for the continual monitoring of these signals (Biopac System, Santa Barbara, 
CA). Data was then saved on a computer for subsequent analysis.  
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Absolute SkBF response at baseline and during the plateau phase was initially 
assessed by averaging over a stable 2 and 5 minute period of red cell flux at the end of 34 
and 40°C respectively. The initial peak response was calculated as the average of the 
maximal one minute response during the peak period for both 40 and 43°C. CVC was 
then calculated as the ratio of SKBF red cell flux to MAP. Subsequent data analysis 
involved averaging red cell flux over the entire 30 minutes of the 40°C heating stage. In 
both cases, data was then normalized by comparing it to either absolute SkBF or CVC 
during the last 5 minutes at 43°C (as a percentage of maximal response) and this 
represents TR. 
 
Statistical Analysis. All data are presented as means ± SEM unless otherwise stated. 
Baseline subject characteristics were those obtained under fasting conditions during rest 
on day 1 and were compared using unpaired t-tests. The acute effect of flavanols on 
hemodynamic variables, absolute SkBF response and CVC, along with relative SkBF 
response and CVC were assessed using a multi-factorial, repeated measures ANOVA 
with 1 between subject factor (age) and up to 3 within subject factors (treatment, time and 
stage). The chronic effect of flavanols on all variables was assessed using a mixed model 
ANOVA with 1 random effect (subject) and 2 fixed effects (treatment and stage). A 
mixed model was used because it allowed us to keep one of the subjects in the model 
who was only able to complete one of the chronic interventions. In all cases, when a 
significant interaction was observed, a Bonferroni adjustment for multiple comparisons 
was used to identify significant mean differences in the applicable pair wise comparisons. 
In cases where the assumption of sphericity was violated a Huynh-Feldt corrected 
degrees of freedom was used to determine significance. The level of significance was set 
a priori at p<0.05. 
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RESULTS 
Baseline Differences in Young and Older Individuals. Subject characteristics are 
presented in Table 1.2. Baseline systolic, diastolic and mean arterial blood pressure along 
with total cholesterol and low-density lipoprotein were all significantly higher in the 
older individuals (p<0.05). There was a significant difference in mean skin temperature at 
the interface between the heating unit and skin surface for the different heating stages as 
expected (34.1 ± 0.04°C, 38.9 ± 0.07°C and 41.0 ± 0.10°C, p<0.001 for all pair wise 
comparisons). However, there was no significant difference in skin temperature for a 
given stage under any other condition: flavanol versus placebo, pre- versus post-ingestion 
or young versus older individuals (p>0.05 for all).  
There was no significant difference in absolute SkBF response to local heating 
between young and older individuals during any stage of heating (p>0.05 for all). 
However, there was a significant difference in absolute CVC response to local heating 
between young and older individuals during the plateau phase of 40°C heating (p<0.05) 
but not during 34°C or the final 5 minutes of 43°C heating (p>0.05 for both). Figure 1.1 
demonstrates the effect of age on relative TR; it shows no difference between young and 
older individuals in relative CVC in response to local heating at 34°C (10.8 ± 0.6% 
versus 11.9 ±0.7%, p>0.05); however, older individuals demonstrated a reduced response 
during the plateau phase at 40°C (72.1 ± 2.9% versus 62.0 ± 3.0%, p<0.05). This same 
response was seen in relative SkBF.  
 
Acute Effects of Flavanol Ingestion. There was no treatment effect on any hemodynamic 
variables (HR, SBP, DBP or MAP) or on absolute or relative SkBF or CVC responses. 
Figure 1.2 shows the unexpected finding that there was a significant difference pre- 
versus post-ingestion of flavanols on relative initial peak SkBF response to 40°C (62.5 ± 
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1.7% versus 67.6 ± 2.4%, p<0.05) that was not present following ingestion of the placebo 
(64.0 ± 2.0% versus 60.7 ± 2.1%, p>0.05). Further investigation of this interaction 
revealed that there was also a significantly different initial peak response at 40°C post-
ingestion when comparing flavanols and placebo (67.6 ± 2.4% versus 60.7 ± 2.1%,  
p<0.01) that was not present pre-ingestion of the test drink (62.5 ± 1.7% versus 64.0 ± 
2.0% versus p>0.05). There was no difference in response between young and older 
individuals. 
Figure 1.3 is a SkBF tracing from a representative subject pre- and post-flavanol 
ingestion. In order to investigate the unexpected finding that there was a significant effect 
of treatment during the relative initial peak SkBF response to 40°C heating but not during 
relative SkBF or CVC, both of which focus on the final 5 minutes of the plateau phase of 
the response, we re-analyzed the data. We averaged the entire SkBF response during the 
30 minutes of 40°C heating and normalized it to the SkBF response achieved during the 
last 5 minutes at 43°C. Figure 1.4 demonstrates that this significant effect of flavanols on 
TR persists when the entire 30 minutes of heating at 40°C is considered. There remains a 
significant increase in SkBF response following flavanol ingestion (52.4 ± 2.1% versus 
56.1 ± 2.0%, p=0.05) but not ingestion of the placebo (54.2 ± 2.4% versus 52.7 ± 2.1%, 
p>0.05).  It is important to note that older individuals continue to show an attenuated 
response compared with the young when the entire response during 40°C is considered 
(58.4 ± 2.5% versus 49.3 ± 2.6%, p<0.05). 
 
Chronic Effect of Flavanol Ingestion. Baseline subject characteristics are presented in 
Table 1.3. There was no effect of chronic flavanol ingestion on any of the blood analytes. 
There was a significant difference in mean skin temperature at the interface between the 
heating unit and skin surface for 34, 40 and 43°C as expected (34.1 ± 0.12°C, 38.9 ± 
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0.12°C and 41.2 ± 0.12°C, p<0.001 for all pair wise comparisons). However, there was 
no significant difference in skin temperature for a given stage following chronic ingestion 
of either flavanols or the placebo (p>0.05 for all). There was also no significant 
difference in TR following chronic ingestion of flavanols.  
Figure 1.5 shows there was a main effect of treatment on systolic and diastolic 
blood pressure; both were significantly lower following chronic flavanol consumption 
compared with initial baseline values (Systolic Baseline: 126 ± 4mmHg versus Flavanols: 
119 ± 4mmHg, p<0.001; Diastolic Baseline: 80 ± 3mmHg versus Flavanols: 77 ± 
3mmHg, p<0.05). There was no difference in systolic or diastolic blood pressure 
following ingestion of the placebo. MAP also decreased following chronic ingestion of 
flavanols compared with baseline and this effect was not seen following ingestion of the 
placebo (Baseline: 95 ± 3mmHg, Placebo: 94 ± 3mmHg, Flavanols: 91 ± 3mmHg, 
p<0.001).  
 
DISCUSSION 
The significant findings of the present study were as follows: 1) at baseline older 
individuals demonstrated a reduced SkBF response to local heating compared with the 
young supporting the initial premise of impaired endothelial function in the older group, 
2) consumption of flavanols led to an acute augmentation of the SkBF response to local 
heating; however, this effect was not different between the young and older individuals, 
and 3) there was no effect on SkBF response to local heating following chronic exposure 
to flavanols; however, there was a significant reduction in both systolic and diastolic 
blood pressures in older individuals. 
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Baseline Differences in Young and Older Individuals. Absolute CVC was reduced in 
response to 40°C local heating in older individuals but was not different from the young 
at either 34 or 43°C. This suggests that the young and older individuals did not differ at 
baseline and that both groups achieved the same maximal vasodilatory response to 
heating at 43°C. As expected, older individuals did demonstrate a reduced cutaneous 
vasodilatory response to local heating compared with the young (30, 145).  
 
Acute Effects of Flavanol Ingestion. The goal of this study was to examine the acute 
effects of flavanol ingestion on the cutaneous vasodilator response to local heating and to 
determine if the response to heating differed in young versus older individuals. Contrary 
to our hypothesis there was no effect of flavanols on TR in either young or older 
individuals when only the final, stable 5 minutes of the plateau phase during 40°C were 
considered.  
An unexpected finding was that flavanols did lead to an acute, significant increase 
in the relative initial peak SkBF response to local heating at 40°C. This effect was not 
seen following ingestion of the placebo nor was it present during the initial peak response 
to 43°C. Studies have shown that the initial peak response is primarily neurally-mediated 
with less of a contribution from NO, whereas the plateau phase has a much greater 
contribution from NO (106, 144). Therefore, we had initially hypothesized that we would 
see the effect of flavanols in the latter phase.  
In order to further investigate this unexpected finding we averaged the entire 
SkBF response during the 30 minutes of 40°C local heating and normalized it to the 
SkBF response achieved during the last 5 minutes at 43°C. We hypothesized that we 
were detecting an effect of flavanols only during the initial peak because the overall 
response to local heating was less then than during the plateau phase so it represented a 
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greater fractional change. However, NO bioavailability was still being enhanced over the 
entire 30 minutes.  
Figure 1.3 is a SkBF tracing from a representative subject pre- and post-flavanol 
ingestion that displays this hypothesized effect. In support of our hypothesis, the 
significant effect of flavanols was not lost when the entire SkBF response to 30 minutes 
of 40°C local heating was considered. We believe the effect of flavanols was occurring 
not only during the initial peak, though it may have appeared more robust, but rather 
there was some effect on cutaneous vasodilatory response throughout the 30 minutes at 
40°C.  
It is important to note that we observed the previously reported significantly 
attenuated SkBF response to 40°C in the older individuals compared with the young at 
baseline even when the SkBF response throughout the 30 minutes of 40°C local heating 
was considered. This method of data analysis differs from that reported in the literature, 
which involve the analysis of only the final 5 minutes of the plateau phase of the response 
and not the response over the entire 30 minutes. However, NO is shown to have some 
contribution to the cutaneous vasodilatory response throughout the entire heating phase 
as is evidenced by studies where the entire response is significantly blunted by the 
administration of L-NAME prior to local heating (106, 144).  
We believe our results are strengthened by our study design: TR was assessed 
pre- and post-ingestion of the test drink on the same day under the same conditions; the 
study was placebo-controlled; and this augmentation in TR was not seen following 
ingestion of the placebo. In addition, the expected impairment in TR persisted prior to 
flavanol ingestion between our young and older groups. 
The exact mechanism by which flavanols augment NO bioavailability has not yet 
been fully elucidated but a number of indirect pathways based on the synthesis and/or 
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degradation of NO have been hypothesized. These include: 1) interaction with endothelial 
nitric oxide synthase (eNOS) thereby maintaining the enzyme in an activated form so it is 
available to continually produce NO, 2) by decreasing arginase activity as it shares the  
substrate L-arginine with eNOS so this effectively leads to the preservation of 
intracellular concentration of L-arginine, and/or 3) by inhibiting NADPH oxidase (NOX) 
as it is the primary enzyme responsible for the generation of superoxide anion thereby 
reducing oxidative stress (71, 89, 177).  
This study was not mechanistic by design so we can only speculate on which of 
these mechanisms may have been underlying this augmentation in TR following flavanol 
ingestion. eNOS has been shown to be the primary isoform responsible for the generation 
of NO during local heating; however its involvement in the initial peak SkBF response 
has been questioned (107, 183). In our study it appears as though flavanols were exerting 
some effect over the entire phase of 40°C local heating, including the initial peak, 
suggesting it is less likely that eNOS activation was the primary mechanism.  
Dupont et al. demonstrated that the SKBF plateau phase of 40°C heating 
increased following the administration of both ascorbic acid and L-arginine whereas the 
initial peak response increased following the administration of ascorbic acid only (60). 
Free radicals, including the superoxide anion, lead to a reduction in NO bioavailability as 
they react with NO to form peroxynitrite (16, 17). Flavanols have been shown to improve 
NO bioavailability via the inhibition of NOX (20, 191, 193), a major producer of 
superoxide anions in the endothelium (33). In the study by Dupont et al., the effects of 
ascorbic acid were seen during the initial peak along with the plateau, suggesting the 
possibility that the effect of flavanols in our study may be due to NOX inhibition. 
Mechanistic studies are required to confirm this.  
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There was no difference between the young and older individuals in their acute 
response to flavanol ingestion. It is known that older individuals have higher levels of 
oxidative stress so we might expect a greater effect of flavanols in older individuals 
compared with young if flavanols were working via inhibition of NOX. However, in 
order to limit confounders we specifically recruited older individuals who were taking 
little or no medication and who had not been diagnosed with CVD or any other metabolic 
illness. Not by coincidence, such individuals generally lead health-conscious lifestyles 
and their diet and physical activity levels reflect this. Though none of the older 
individuals in the study were highly trained, we believe they represented a healthier 
segment of the aging population.  
 
Chronic Effects of Flavanol Ingestion. Contrary to our hypothesis there was no 
significant difference in cutaneous vasodilatory response to local heating following 
chronic ingestion of flavanols in older individuals. Compliance needs to be considered 
with long term, at home interventions such as this. In this study, subjects were asked on 
each of their testing days whether they had consumed all of the test drinks in the prior 28 
days and whether the time of day of consumption was kept consistent. Only a single 
subject admitted to missing a drink and all subjects complied with the request to return 
empty canisters and unused product. This suggests that compliance was exceptional so 
we do not believe that a lack of compliance is playing a role in our results.  
There is the possibility that the length of flavanol exposure was not long enough 
to lead to cutaneous microvascular effects; however, the 28-day study period did result in 
a decrease in blood pressure. This provides evidence that, though there was no effect on 
TR, the quantity of flavanols and the length of time they were taken was sufficient to lead 
to a beneficial vascular effect. A number of meta-analyses have concluded that flavanols 
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have a blood pressure lowering effect (164, 200). The theory behind this effect is that 
decreases in NO steady-state concentration can lead to a failure in smooth muscle 
relaxation and subsequent hypertension.  
 
Limitations. One of the limitations in the current study is the use of 43°C local heating to 
elicit maximal vasodilatory response for data normalization. This study did not involve 
the insertion of microdialysis membranes so the administration of sodium nitroprusside 
was not possible. We believe this was not a true limitation because absolute CVC was not 
different between young and older individuals suggesting that they had the same 
vasodilatory capacity. There are a number of published studies that demonstrate that 
43°C local heating elicits a maximal SkBF response (29, 48, 106).  
A second limitation of our study was the inability to calculate relative CVC for 
the analysis of the response over the entire 30 minutes of 40°C heating. We took 
intermittent blood pressure in the final 3 minutes of each stage but we did not take beat-
by-beat blood pressure throughout the entire 30 minutes so calculation of CVC was not 
possible. Calculation of conductance is important as changes in blood pressure can lead 
to changes in blood flow without vasodilation. However, analysis of the intermittent 
blood pressures taken at the end of each stage demonstrated no significant changes 
throughout the course of the heating protocol. This suggests that, in this case, flow would 
be representative of conductance. Furthermore, at baseline both relative SkBF response 
and relative CVC in the final 5 minutes of the plateau phase were significantly attenuated 
in older individuals compared to younger suggesting minimal effects of blood pressure. 
Our lab has also done some pilot work in which we have demonstrated that blood 
pressure does not change during the initial peak response to heating at 40°C (unpublished 
data).  
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Conclusions / Perspectives. Our main finding was that the ingestion of flavanols acutely 
improved the vasodilatory capacity of the cutaneous microvasculature in response to 
local heating and that this effect was not significantly different in young and older 
individuals. There was no effect on the cutaneous vasodilatory response to local heating 
following chronic exposure to flavanols, though beneficial vascular effects were seen by 
a reduction in blood pressure. The results from this study contribute to current research 
by providing further support for vascular health benefits associated with flavanols. 
Further mechanistic studies are warranted to elucidate underlying mechanisms as they 
could potentially guide future pharmacological research.   
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TABLES AND FIGURES 
Table 1.1  
Nutritional Composition of Test Drinks 
 
 
Per serving Flavanol Placebo
Calories 149 153
Fat, g (calculated) 2 0
     Sat fat, g 1 0
     Trans fat, g 0 0
Cholesterol, mg 11 12
Sodium, mg 364 370
Carbohydrates, g 25 26
     Dietary fiber, g 5 5
     Sugar, g 17 20
Protein, g 14 14
Vitamin A, IU 10 8
Vitamin C, mg 2 3
Calcium, mg 429 486
Iron, mg 1 0
Magnesium, mg 113 41
Potassium, mg 780 676
Total Flavanols, mg 528.0 0.0
     Proanthocyanidins 1-10, mg 247.2 0.0
            PACs 1 mers 64.8 0.0
                 Catechin, mg 17.8 0.0
                 Epicatechin, mg 47.0 0.0
            PACs 2 mers 39.8 0.0
            PACs 3 mers 25.4 0.0
            PACs 4 mers 26.4 0.0
            PACs 5 mers 22.1 0.0
            PACs 6 mers 20.6 0.0
            PACs 7 mers 18.7 0.0
            PACs 8 mers 12.0 0.0
            PACs 9 mers 9.6 0.0
            PACs 10 mers 7.7 0.0
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Table 1.2 
Subject Characteristics; Acute 
 
 
  
Young Old
Sex, M/F 8/7 7/8
Age (yrs) 23 ± 3 69 ± 5 
Height (m) 1.71 ± 0.09 1.68 ± 0.10
Weight (kg) 68.1 ± 13.0 65.9 ± 12.2
BMI (kg/m2) 23.1 ± 2.8 23.1 ± 3.2
Glucose (mg/dL) 86 ± 4 90 ± 9
Total Cholesterol (mg/dL) 166 ± 30 200 ± 24#
Triglycerides (mg/dL) 76 ± 28 76 ± 29
LDL (mg/dL) 91 ± 25 117 ± 27*
HDL (mg/dL) 60 ± 15 69 ± 19
Heart Rate (bpm) 65 ± 10 67 ± 14
SBP (mmHg) 115 ± 12 125 ± 10*
DBP (mmHg) 71 ± 9 78 ± 9*
MAP (mmHg) 85 ± 9 94 ± 8#
Values are means ± SD, n=15 per group. M, male; F, female; BMI, 
body mass index; LDL, low density lipoprotein; HDL, high density 
lipoprotein; SBP, systolic blood pressure; DBP, diastolic blood 
pressure; MABP, mean arterial pressure. *p<0.05 and #p<0.01 
compared with young.
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Table 1.3 
Effect of Chronic Ingestion of Flavanols 
 
 
  
Baseline Placebo Flavanol
Sex, M/F 3/8
Age (yrs) 68 ± 3
BMI (kg/m2) 22.3 ± 2.8 22.0 ± 2.8 22.1 ± 2.6
Glucose (mg/dL) 87 ± 8 84 ± 8 82 ± 10
Total Cholesterol (mg/dL) 197 ± 20 189 ± 37 195 ± 30
Triglycerides (mg/dL) 64 ± 25 68 ± 30 68 ± 27
LDL (mg/dL) 110 ± 20 109 ± 31 111 ± 27
HDL (mg/dL) 74 ± 18 67 ± 19 71 ± 16
Values are means ± SD, n=11. M, male; F, female; BMI, body mass index; LDL, low 
density lipoprotein; HDL, high density lipoprotein. 
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Figure 1.1  
   
 
 
 
  
Figure 1.1: A summary of relative skBF and CVC responses to local heating in young and old individuals. The 
stage*age interaction was significant for both skBF and CVC, p<0.01. A pair wise comparison showed the mean 
difference in relative skBF and CVC responses at 40°C to be significantly different between young and old, after a 
bonferroni adjustment for multiple comparisons. *p<0.05 compared with young at same LocTemp. Values (means ± 
SEM) are expressed as a  percentage of maximal skBF achieved during the last 5 minutes of 43°C heating.
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Figure 1.2  
 
 
 
 
 
  
Figure 1.2: A summary of the relative initial peak SkBF response to  40°C pre- versus post-ingestion of the test 
drinks. The treatment*time*stage interaction was significant, p<0.05, and a pair wise comparison showed the mean 
difference in relative initial peak response to 40°C to be significantly higher following ingestion of flavanols, after a 
bonferroni adjustment for multiple comparisons. There was no treatment effect on the initial peak response to 43°C 
heating. *p<0.05 compared with pre in same treatment, #p<0.01 compared with placebo post-ingestion. Values (means 
± SEM) are expressed as a  percentage of maximal skBF achieved during the last 5 minutes of 43°C heating.
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Figure 1.3  
 
 
 
 
  
Figure 1.3: A representative tracing of the skin blood flow (skBF) response during the local heating protocol pre- and 
post-flavanol ingestion of a single subject. The arrows indicate the beginning and the end of 40°C heating. It appears as 
though there is an increase in skBF response following flavanol ingestion during the 30 minutes of 40°C heating that is 
not present at 34°C or 43°C .  
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Figure 1.4  
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Figure 1.4: A summary of the relative SkBF response to 30 minutes of local heating at 40°C. There remained a 
significant interaction effect of treatment*time*stage, p<0.05 and a pair wise comparison showed the mean difference 
in relative skBF response to be significantly higher following flavanol consumption, after a bonferroni adjustment for 
multiple comparisons. There was no significant difference in response following ingestion of the placebo. *p<0.05 
compared with pre of same treatment. Values (means ± SEM) are expressed as a percentage of the average response 
during 30 minutes of local heating at 40°C to the maximal skBF achieved during the last 5 minutes of 43°C heating.
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Figure 1.5 
 
 
 
  
Figure 1.5: A summary of the effect of chronic flavanol ingestion on SBP and DBP. Both SBP and DBP decreased 
significantly following chronic exposure to flavanols but not the placebo. ^p<0.001 and *p<0.05 compared with baseline. 
Values are means ± SEM. 
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Chapter V: Study #2 
Cerebrovascular Response to the Acute and Chronic Ingestion of Flavanols in 
Young and Older Humans: Role of Nitric Oxide 
ABSTRACT 
Aging is associated with a progressive decline in endothelial function that 
contributes to cardiovascular disease (CVD) risk. Lifestyle choices, including nutrition, 
are known to modulate the progression of CVD. Cerebral endothelial function has been 
shown to be impaired in individuals with CVD, it is correlated with the severity of the 
disease, and studies have shown that endothelial function is reversible with certain 
interventional strategies. NO has been shown to be a contributor to basal cerebral blood 
flow (CBF) tone and endothelium-dependent vasomotor function reflects the integrity of 
the endothelial layer and hence can be used as a surrogate of NO bioavailability. 
Therefore, in this study basal CBF and CBF response to hypercapnia (cerebral vasomotor 
reactivity; CVMR) were used to assess cerebral vascular endothelial function. This study 
investigated the effect of flavanols (~ 528mg, The Hershey Company) on cerebral 
vascular function with aging following both acute and chronic exposure. It was 
hypothesized that older individuals would exhibit both a reduced CBF and CVMR 
compared with the young at baseline, both of these measures would be acutely restored 
following flavanol ingestion in the old, and they would also be increased following 
chronic flavanol exposure in older individuals. Transcranial Doppler was used to assess 
baseline CBF and CBF response to hypercapnia (CVMR), achieved via a rebreathing 
technique. Cerebral vascular conductance index (CVCi) was calculated as the ratio of 
CBF velocity to MAP.  For the acute portion of the study, 10 young (ages 19-28) and 10 
older individuals (ages 65-77) were tested on two separate days. They were provided with 
either a nutrient-matched placebo or a flavanol-containing test drink (randomized order, 
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double-blinded) and CBF and CVMR were assessed pre-ingestion and 2.5 hours post-
ingestion. For the chronic portion of the study, 6 older individuals (ages 65-71) were 
recruited. CBF and CVMR were assessed at baseline and then following 28 days of 
flavanol consumption. As expected, prior to flavanol ingestion older individuals 
demonstrated a reduced CVCi compared with the young (0.85 ± 0.04 cm/s*mmHg versus 
0.55 ± 0.04 cm/s*mmHg p=0.001) along with a reduced CVCi-CVMRmax (8.6 ± 0.6 
versus 6.9 ± 0.4, p=0.05). This supports the premise of impaired endothelial function in 
the older individuals. Acutely following flavanol ingestion there was a significant 
decrease in CVCi (0.71 ± 0.04 cm/s*mmHg versus 0.62 ± 0.04 cm/s*mmHg p<0.05) and 
CVCi-CVMRmax (8.6 ± 0.6 versus 6.1 ± 0.5, p=0.001). This unexpected effect was seen 
in both young and older individuals and requires further investigation. There was a 
significant increase in CVCi following chronic exposure to flavanols in older individuals 
(baseline, 0.60 ± 0.05 cm/s*mmHg versus flavanols, 0.72 ± 0.06 cm/s*mmHg p<0.05) 
suggesting an increase in basal NO bioavailability. However, there was no effect of 
chronic flavanol ingestion on CVMR in older individuals. Though further mechanistic 
studies are required, these data provide preliminary evidence for cerebral vascular health 
benefits associated with chronic flavanol ingestion.  
 
INTRODUCTION 
Cardiovascular disease (CVD) is currently the number one cause of mortality in 
the US and its incidence increases significantly with age in both males and females (167). 
Taking into account only coronary heart disease, hypertension and stroke, the estimated 
direct and indirect costs associated with the treatment of these diseases were already 
about 300 billion dollars annually in 2008 (167). As aging is one of the primary risk 
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factors for CVD it is of considerable concern that that the number of individuals over 65 
years of age is projected to go from accounting for 13% of the overall population in 2010 
to 20% of a much greater population in 2050 (212).  
One of the underlying pathologies of CVD is atherosclerosis. Arterial endothelial 
dysfunction is believed to be one of the primary events in the development of 
atherosclerosis as the endothelium plays an integral role in maintaining vascular 
homeostasis (80). Endothelial dysfunction has been shown to be associated with 
atherosclerotic risk factors (38, 213) and is believed to be a predictor of adverse CV 
events (80, 197). This dysfunction is believed to be due to a decreased bioavailability of 
nitric oxide (NO) as it is the release of NO that mediates many of the protective functions 
exerted by an intact endothelium (152). In parallel with the increased risk of CVD, aging 
is also associated with a progressive decline in endothelial function that is evident by a 
reduced bioavailability of NO (39, 155). This impairment extends to the cerebral 
circulation; NO has been shown to be involved in CBF tone (99, 102, 116) and has been 
shown to be reduced with aging (13, 163, 168). Specifically, there is evidence that 
endothelial dysfunction results in impaired vasodilation in the cerebral vasculature 
thereby leading to dysfunction in CBF regulation (117, 185, 211). Thus, endothelium-
dependent vasomotor function in the cerebral circulation, CBF response to hypercapnia 
(CVMR), reflects the integrity of the endothelial layer and can be used as a surrogate of 
NO bioavailability.  
There is compelling evidence that environmental factors such as nutrition are key 
modulators to the progression of CVD (156). The endothelium constitutes the 
predominant tissue to which nutrient molecules are exposed following digestion and 
absorption and thus it represents a potential site of action for ingested compounds. Meta-
analyses have shown that increased consumption of plant-based foods decreases risk of 
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CVD, including stroke (52). Health benefit is not believed to be due solely to vitamins 
and minerals, but also to the presence of bioactive compounds called polyphenols; small, 
nonessential molecules that demonstrate disease-preventative properties. Over the past 
decade flavanols, one of the more prevalent family of polyphenols, have become the 
focus of intense research. Flavanols are found in a high concentration in certain fruits and 
in foods such as green tea, red wine, soy, and cocoa products (154). Numerous studies 
have shown that flavanols increase NO bioavailability; in conduit arteries as assessed by 
flow mediated dilation (12, 87, 90, 147) and, in a smaller number of studies, in the 
microcirculation as assessed by peripheral arterial tonometry (67, 180). There is evidence 
to suggest that the underlying mechanism accounting for the increase in NO 
bioavailability may differ between acute and chronic consumption of flavanols.  
Consequently, we investigated both the acute and chronic effects of flavanol 
ingestion on basal CBF and CVMR. The acute portion of the study involved young and 
older individuals and the chronic portion included only an older cohort. A number of 
studies have demonstrated an improvement in endothelial function associated with 
flavanol ingestion; however, whether or not endothelial function can be restored in the 
cerebral circulation following flavanol ingestion remains unknown. We hypothesized that 
the older individuals would have a reduced basal CBF and an impaired CVMR at 
baseline compared with the young but that they would both be acutely restored to the 
level of the young following flavanol ingestion. In addition, we hypothesized that these 
impairments would be improved at baseline following chronic flavanol consumption in 
the older individuals. 
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METHODS  
Subjects. For the acute portion of the study, 10 young (ages 19-28; 5 men) and 10 older 
(ages 65-77; 5 men) individuals were recruited to participate (see Table 2.1 for subject 
characteristics). Each visited the laboratory for testing on 2 separate days. In order to 
control dietary intake of flavanols prior to testing subjects were asked to do the 
following: 1) avoid flavanol-rich foods including chocolate/cocoa products, green tea, red 
wine and most fruits in the 3 days prior to the study and 2) document all food intake on 
the day prior to their testing day so they could consume a similar diet prior to day 2 of 
testing (157, 158). Subjects came into the laboratory at approximately the same time for 
their 2 testing days following a 12 hour fast, having refrained from caffeine and exercise 
for 24 hours. None of the young women were on birth control and all were tested during 
the early follicular phase of their menstrual cycle (41). All of the older women were 
postmenopausal. All subjects were healthy, nonsmokers with no diagnosed 
cardiovascular disease. None of the younger subjects were taking medications; however, 
7 of the older subjects were on medications and they refrained from taking them on the 
morning of each of their testing days.  
For the chronic portion of the study, 6 older individuals (ages 65-71; 1 man) were 
recruited, 4 of whom were also part of the acute portion of the study. Subjects were 
provided with enough drink powder to consume a test drink at home for 28 days. They 
were not asked to follow any specific dietary restrictions during that time; however, they 
were asked to consume the test drink at approximately the same time each day (morning, 
afternoon or evening). They were also asked to return to the laboratory with empty 
canisters and unused product. Subjects came in for testing within 3 days of consuming 
their 28th drink, following a 12 hour fast, having refrained from caffeine and exercise for 
24 hours.  
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Prior to its commencement, the consent form and study procedures were approved 
by the Institutional Review Board at the University of Texas at Austin. 
 
Instrumentation. Upon arrival in the laboratory all study procedures and risks were 
explained, questions were answered and then all participants provided informed consent. 
On each study day, height and weight were assessed using a medical–grade seca769 scale 
(seca corp., CA, USA). Subjects were then asked to lie semi-recumbent on the bed and a 
fasting blood sample was drawn from the antecubital fossa so that glucose and lipids 
could be assessed. Following the blood draw, subjects were instrumented with 5 
electrodes. Both cardiac rhythm and heart rate were continuously monitored throughout 
the experimental protocol from an electrocardiogram on a patient monitor (GE DASH 
4000, General Health Care). A blood pressure cuff was placed on the left arm and 
intermittent blood pressure measurements were obtained by auscultation of the brachial 
artery via electrosphygmomanometry (Tango+; SunTech, Raleigh, NC). Mean arterial 
blood pressure (MAP) was calculated as one-third pulse pressure plus diastolic blood 
pressure. A finger blood pressure cuff was placed on the right hand, inflated and 
calibrated allowing for the assessment of continuous beat-by-beat blood pressure using 
the Penaz method (NIBP100D, BIOPAc Systems). A 2-MHz Doppler probe (Multi-flow, 
DWL Elektronische Systeme, Singen, Germany) was adjusted over the temporal window 
of the right middle cerebral artery (MCA).  The placement of the Doppler probe allowed 
for the assessment of the MCA mean blood velocity, which will be denoted as cerebral 
blood flow velocity (CBFV) for the remainder of the document. Once an optimal signal 
was identified the probe was secured to a specially designed head set so it would remain 
stable throughout the rebreathing protocol. Following a minimum of 20 minutes of rest, 
baseline systemic and cerebral hemodynamic measures were assessed in all subjects.  
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Rebreathing Protocol. Following the collection of baseline measures, subjects were fitted 
with a nose clip and were asked to put in a mouthpiece attached to a specialized 3-way 
valve joined to a rubber bag (2100 series, Hans Rudolph, Kansas City, MO). 
Manipulation of the valve directed whether the subject breathed room air or their own 
expired air from the bag. A sampling line attached to this valve assembly allowed for the 
continuous assessment of PETCO2 using a capnograph (VitalCap Capnograph Monitor, 
Oridion, Needham, MA). Subjects were instructed to remain relaxed while breathing 
room air through the mouthpiece for about 2 minutes at which point they were asked to 
take in a larger breath and, prior to expiration, the valve was switched allowing them 
access to only their own expired air for subsequent breathing. The rebreathing procedure 
continued until there had been a minimum of 15 mmHg change in PETCO2, about 2-3 
minutes. During the rebreathing protocol, oxygen was continuously supplied (amount 
calculated based on height, weight and age) and saturation was continually monitored to 
ensure PaO2 remained unaffected (83). All testing was conducted in a temperature 
controlled room (21-24°C).  
 
Acute Effects of Flavanol Ingestion. At the end of the baseline rebreathing protocol, all of 
the instrumentation was removed from the subject except for the ECG leads and the 
brachial blood pressure cuff. As this was a placebo-controlled, double-blinded study 
subjects were then provided a test drink, either flavanol-containing (~528mg) or a 
placebo, by a third party (same nutritional composition as study 1). Drinks were provided 
in powdered form by The Hershey Co., PA, USA, so they were reconstituted with 8oz of 
warm, purified water just prior to consumption as per instructions. All subjects consumed 
the beverage within 10 minutes and a timer was started immediately upon completion. 
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Subjects were asked to remain resting in the semi-recumbent position after consuming the 
test drink. 
Two hours and twenty minutes following ingestion of the test drink, subjects were 
re-instrumented with the finger blood pressure cuff. An optimal CBFV signal was once 
again identified with the Doppler probe and the probe was then secured to the headset. 
This timing was strictly adhered to because plasma flavanols and associated metabolites 
have been shown to peak 2 hours following consumption, and physiological responses to 
flavanol ingestion have been shown to remain maximal for 2-3 hours post-ingestion (12, 
87, 180). The rebreathing protocol was repeated as outlined above.  
Young male and older subjects were scheduled for their second day of testing 
after allowing for a minimum of 3 days ‘washout.’ This length of time has been used in 
other similar studies (12, 147, 180). Young females had to wait for their menstrual cycle 
to begin the following month. For day 2 the experimental protocol was identical to the 
first study day, with the only difference being that the test drink administered was the one 
not given on day 1. The order in which these drinks were provided was randomized.   
 
Chronic Effects of Flavanol Ingestion. Subjects came in for testing within 3 days of 
consuming their 28th drink. There was a minimum of 2 weeks between the interventions 
to avoid potential carry-over effects (88, 157). All instrumentation along with the 
rebreathing protocol was identical to the acute portion of the study. However, during 
these study days the testing measures were done only once while the subject was fasted 
as there was no additional test drink provided.   
      
Blood Analysis. Glucose and lipids were assayed simultaneously using the Cholestech 
LDX analyzer (Inverness Medical, Biosite Inc, CA, USA) within 30 minutes of collection 
 41
into a heparinized vacutainer tube. This point of care analyzer has been validated against 
a hospital reference laboratory (34).  
 
Data Analysis. Analogue output signals from cardiac rhythm, heart rate, continuous blood 
pressure measures and the ultrasound probe were converted, via a data acquisition 
system, to a digital signal allowing for the continual monitoring of these signals 
throughout the testing protocol (Biopac System, Santa Barbara, CA). Data was then 
saved on a computer for subsequent analysis.  
Blood pressures taken at the brachial artery are the reported baseline measures. The 
continuous blood pressure measurements taken at the finger allowed for the breath-by-
breath determination of MAP and the ratio of CBFV to MAP were then used to calculate 
cerebrovascular conductance index (CVCi). Baseline CBFV and CVCi measures were 
assessed by averaging over the final minute of resting prior to the start of the rebreathing 
protocol. CVMR, the response of CBFV (and CVCi) to breath-by-breath changes in 
PETCO2, was assessed by plotting CBFV (or CVCi) as a function of PETCO2. The 
resulting curvilinear relationship was analyzed using a four parameter logistic function as 
outlined by Claassen et al. (44). This allowed for the quantification of model parameters 
that are suggested to have physiological implications: a the range in change of CBFV (or 
CVCi), y0 the maximum of CBFV (or CVCi) achieved during hypercapnia, x0 the level 
of PETCO2 when the slope of the curve is maximal and b the curvilinear properties of the 
line of best fit. Additionally, the first order derivative of the logistic function used for the 
curve fitting generated a bell-shaped curve and the peak of that curve represented CBFV-
CVMRmax (or CVCi-CVMRmax). Nonlinear curve fitting was performed using Simplex & 
Levenberg-Marquardt algorithms (Model & Analyze, VUV Analytics). Nonlinear curve 
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fitting was chosen over linear regression as it has been shown to be a better model of the 
physiological response of CBFV (or CVCi) to hypercapnia (44). 
 
Statistical Analysis. All data are presented as means ± SEM unless otherwise stated. A 
paired t-test showed no significant differences in systemic and cerebral hemodynamic 
variables obtained under fasting conditions during rest on each of the study days so these 
data were averaged and represent baseline values. Differences between young and older 
individuals were then compared using unpaired t-tests and are presented in Tables 2.1 and 
2.2. The acute effect of flavanols on systemic and hemodynamic variables were assessed 
using a multi-factorial, repeated measures ANOVA with 1 between subject factor (age) 
and 2 within subject factors (treatment and time). The chronic effect of flavanols on all 
variables was assessed using a repeated measures ANOVA with treatment as the main 
effect. In all cases, when a significant interaction was observed, a Bonferroni adjustment 
for multiple comparisons was used to identify significant mean differences in the 
applicable pair wise comparisons (SPSS, version 19.0; IBM, New York, NY). The level 
of significance was set a priori at p<0.05. 
 
RESULTS 
Baseline Characteristics. Subject characteristics at baseline are presented in Table 2.1 
while Table 2.2 lists the baseline values for CBFV and CVCi as well as for model 
parameters obtained during the rebreathing protocol. Baseline systolic and MAP were 
significantly higher in the older group (p<0.01) as were total cholesterol and diastolic 
blood pressure (p<0.05). The older group had a significantly lower CBFV and CVCi at 
baseline compared with younger individuals (p=0.001 for both). In response to the 
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baseline rebreathing protocol, older subjects also demonstrated more of a linear response 
(both CBFV-b and CVCi-b were decreased, p<0.05) and a reduced CVMR (CVCi-
CVMRmax, p=0.05).  
 
Acute Effects of Flavanol Ingestion. There was no significant difference in BMI between 
young and older individuals at baseline or between study days. There was also no 
significant difference in any systemic hemodynamic variables (HR, SBP, DBP, and 
MAP) following the acute ingestion of flavanols. Figure 2.1 demonstrates there was a 
significant decrease in CBFV acutely following flavanol ingestion (62 ± 3 versus 54 ± 3 
cm/s, p<0.01) that was not present following ingestion of the placebo (60 ± 3 versus 59 ± 
3 cm/s, p>0.05). The same response was seen with CVCi; a significant decrease acutely 
following flavanol ingestion (0.71 ± 0.04 versus 0.630 ± 0.04 cm/s*mmHg, p<0.05) but 
not the placebo (0.69 ± 0.04 versus 0.66 ± 0.04 cm/s*mmHg, p>0.05). This effect was 
not different between young and older individuals. The treatment*time interaction was 
only trending towards significance with CVCi, p=0.15, compared with CBFV, p=0.05; 
however, we felt the investigation of this former pair wise comparison was warranted due 
to the significance of CBFV.  
 Figure 2.2 demonstrates there was also a significant decrease in CBFV-CVMRmax 
acutely following flavanol ingestion (9.1 ± 0.6 versus 7.0 ± 0.6, p<0.01) but not ingestion 
of the placebo (7.5 ± 0.5 versus 7.7 ± 0.5, p>0.05). Once again, the same response was 
seen with CVCi-CVMRmax (flavanol: 8.6 ± 0.6 versus 6.1 ± 0.5, p=0.001 compared with 
placebo: 6.9 ± 0.5 versus 7.1 ± 0.6, p>0.05). With both these measures there was a 
significant treatment*time interaction, p<0.05, prior to investigation of these pair wise 
comparisons. Further investigation of this interaction revealed there was also a significant 
difference in the pre-ingestion measures on the 2 study days (p<0.05). The R2 value was 
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not significantly different between any of these comparisons nor was the absolute range 
of PETCO2. Once again, this effect was not different between young and older individuals.  
 
Chronic Effect of Flavanol Ingestion. Baseline subject characteristics, blood analytes and 
systemic hemodynamic variables are presented in Table 2.3. There was no effect of 
chronic flavanol ingestion on any of the blood analytes or hemodynamic variables. 
However, there was a significant increase in CBFV following chronic flavanol ingestion 
(58 ± 2 versus 68 ± 3 cm/s, p<0.01) that was not present following chronic ingestion of 
the placebo (58 ± 2 versus 54 ± 3 cm/s, p>0.05).  
Figure 2.3 demonstrates the same relationship in CVCi (flavanol: 0.60 ± 0.05 
versus 0.72 ± 0.06 cm/s/mmHg, p<0.05 compared with placebo: 0.60 ± 0.05 versus 0.57 
± 0.05 cm/s/mmHg, p>0.05). Figure 2.4 shows the individual and group averaged CVCi 
responses of each of the 6 subjects at baseline and then following chronic ingestion of 
flavanols. There were no significant differences in any of the modified rebreathing 
parameters including the calculated CVMRmax following chronic ingestion of flavanols. 
 
DISCUSSION 
The significant findings of this study were as follows: 1) at baseline older individuals 
demonstrated a reduced CBF and CVMR compared with the young, supporting the initial 
premise of endothelial dysfunction in the older individuals, 2) consumption of flavanols 
led to an apparent acute decrease in both CBF and CVMR in both groups, and 3) chronic 
exposure of flavanols led to an increase in CBF in older individuals but had no effect on 
CVMR.  
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Baseline Differences in Young and Older Individuals. As has previously been 
demonstrated (13, 130, 163, 168, 202), older individuals had a significantly lower CBFV 
and CVCi at baseline compared with younger individuals, along with a decreased 
CVMR. It has been shown that NO contributes to baseline CBF tone and is also involved 
in CVMR (99, 102, 116) so this supports the initial premise of impaired endothelial 
function in older individuals.  
The sigmoidal curve relationship between hypercapnia and CBF indicates that 
CBFV increases steadily along with PETCO2 until it begins to level off at high levels of 
PETCO2. In this protocol, older individuals demonstrated a more linear response (b model 
parameter was significantly lower) indicating they were less likely to plateau within the 
range of PETCO2 attained in this study. Claassen et al. suggested 2 possible mechanisms 
for the plateau response to hypercapnia: there is a peak cerebral vasodilatory response to 
increasing PaCO2 or the vasoconstrictive effects of increasing sympathetic output 
eventually overcome vasodilation (44). We would surmise that it is not peak response 
because we would expect the older individuals to have a reduced vasodilatory capacity as 
a result of a reduction in NO bioavailability. If that were true, they would plateau sooner 
in the protocol, and this was not the case. Increasing sympathetic output overcoming 
vasodilation would only be possible if the older individuals were experiencing less 
sympathetic outflow or having reduced tissue responsiveness during the rebreathing 
protocol than the young. However, sympathetic nerve activity was not assessed in this 
study. Further investigation of the physiology associated with the b model parameter is 
required to determine if one of these hypothesized mechanisms is playing a role.  
 
Acute Effects of Flavanol Ingestion. One of the goals of this study was to examine the 
acute effects of flavanol ingestion on cerebral function and to determine if these cerebral 
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effects differed in young versus older individuals. An unexpected finding was that 
flavanol ingestion resulted in an acute, significant decrease in baseline CBFV and CVCi, 
and that this response was the same in the young and older individuals. Our hypothesis 
was that flavanols would cause vasodilation due to an increase in NO bioavailability. 
However, we hypothesized the vasodilatory response would be further downstream in the 
microvasculature.  
In this study we used CBFV as a surrogate for CBF because we could not 
accurately measure MCA diameter. We made this assumption based on evidence from 
previous studies showing that MCA diameter does not change with changes in PaCO2 
within the range used in this study (77, 182). However, the effect of flavanols on cerebral 
hemodynamics has not yet been investigated so the possibility exists that flavanols were 
causing vasodilation of the MCA. An increase in MCA diameter would provide a 
plausible explanation for these results but requires further investigation. Flavanols have 
been shown to have a vasodilatory affect on the brachial artery, also a conduit artery, in a 
number of studies (12, 87, 147). The fact that the acute effect of flavanols on CBFV and 
CVCi was not different between young and older individuals suggests that the 
impairment between young and older individuals at baseline was not the same 
mechanism being acutely affected by flavanol ingestion. The explanation requires further 
investigation.  
Also contrary to our hypothesis, there was a significant decrease in calculated 
CVMRmax acutely following flavanol ingestion. Again, this effect was not different 
between the young and older individuals. The R2 values ranged from 0.96 – 0.97 and 
were not different between treatments indicating that the fit to the nonlinear regression 
was not a factor in these results. The absolute range of PETCO2 that subjects experienced 
during their rebreathing protocol was also not different between treatments indicating that 
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their hypercapnic stimulus was equivalent. A potentially confounding variable was that 
the pre-ingestion values on each of the treatment days were different; significantly higher 
on the day the flavanol-containing test drink was provided when compared with the 
placebo day.  
We believe that our observed decrease is CVMRmax remains significant based on 
the strength of the study design. On each testing day post-ingestion measures were 
assessed in relation to pre-ingestion measures taken on the same day under the same 
conditions. This should account for any variability between the 2 intervention days. 
Furthermore, this study was placebo-controlled and the decrease from pre-ingestion 
values was not seen following the ingestion of the placebo.  
A number of studies have shown that CVMR is impaired in individuals with 
endothelial dysfunction and/or vascular disease (117, 185, 211) so the present findings 
would suggest that flavanols were having an acute adverse effect. However, the 
preponderance of evidence regarding flavanols suggests an acute positive vascular benefit 
so we believe that this effect warrants further investigation.  
 
Chronic Effects of Flavanol Ingestion. Older individuals demonstrated a significant 
increase in both CBFV and CVCi following 28 days of daily flavanol consumption. 
Though this is opposite the response seen acutely following flavanol ingestion it is not 
surprising as there is evidence to suggest that the underlying mechanism accounting for 
the increase in NO bioavailability differs between acute and chronic consumption of 
flavanols. This belief is supported by studies that demonstrate an increase in basal NO 
following long-term flavanol consumption that increases even further following an acute 
dose of flavanols (12, 67, 88). Acute vascular effects are postulated to be mediated 
through the inhibition of NADPH oxidase thereby limiting oxidative stress. Chronic 
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effects are believed to lead to increased levels of activated eNOS or decreased arginase 
activity within endothelial cells (177, 178). The chronic effect is believed to be an 
adaptive response to continuous high-flavanol exposure and therefore, mediated by 
changes in gene expression and protein synthesis or breakdown (194).  
As previously stated, NO contributes to tonic cerebral vascular tone so it is 
possible that the observed increase at baseline is due to an increase in basal NO having an 
effect on the cerebral microvasculature as hypothesized. Determination of which of the 
possible pathways is involved is outside the scope of the current study and requires 
further mechanistic investigation.  
 There was no effect on any of the CVMR model parameters or calculated 
CVMRmax in older individuals following chronic exposure to flavanols. However, if the 
effect on NO bioavailability was not as robust as that seen with baseline CBFV and CVCi 
then there is a possibility that we did not detect it due to the small sample size. Four 
subjects had to be eliminated from analysis due to poor signal quality.  
 
Methodological Considerations. As previously stated, the current investigation used 
MCA mean blood velocity to assess cerebral blood flow. It is recognized that velocity is 
not flow; however, if the diameter of the insonated vessel does not change then a linear 
relationship exists between the two. Previous reports indicate that the diameter of large 
cerebral arteries such as the MCA do not change during an array of perturbations that 
include changes in PaCO2 (77, 182). Furthermore, other methods have validated that 
changes in CBFV correspond to changes in CBF following vasodilatory stimuli (22, 51). 
However, the effect of flavanols on MCA diameter has not specifically been studied so it 
is possible that there was an effect on the diameter of the MCA following acute flavanol 
ingestion. 
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A second consideration is whether PETCO2 was an accurate surrogate for PaCO2 
such that changes in PETCO2 reflected changes in PaCO2. As it has previously been 
demonstrated that PaCO2 and PETCO2 are similar over a range of hypercapnic stimuli and 
respiratory rates, we believe this to be a reasonable assumption (101).  
 
Limitations. We recognize that the significant increase in CBFV and CVCi following the 
chronic ingestion of flavanols involved only a small number of subjects (n=6). However, 
we believe this result is strengthened by the fact that an increase was seen in all six 
individuals so it was not being skewed by only a single individual.  Additionally, this 
response was not seen following 28 days of ingesting the placebo.  
 
Conclusions / Perspectives. Our main finding was that chronic exposure to flavanols 
resulted in a significant increase in baseline cerebral hemodynamics in older individuals 
though there was no effect on cerebral reactivity. Further studies are required regarding 
the acute effects of flavanol ingestion on the cerebral vasculature. The results from this 
study contribute to current research by providing support for cerebral vascular health 
benefits associated with chronic exposure to flavanols in older individuals.  
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TABLES AND FIGURES 
Table 2.1 
Baseline Subject Characteristics 
 
 
 
 
 
 
 
 
Young Old
Sex, M/F 5/5 5/5
Age (yrs) 23 ± 3 68 ± 5 
Height (m) 1.7 ± 0.1 1.7 ± 0.1
Weight (kg) 66.3 ± 14.9 68.1 ± 15.0
BMI (kg/m2) 23.0 ± 3.0 23.6 ± 3.8
Glucose (mg/dL) 87 ± 4 90 ± 9
Total Cholesterol (mg/dL) 167 ± 32 201 ± 26*
Triglycerides (mg/dL) 71 ± 25 78 ± 31
LDL (mg/dL) 94 ± 25 119 ± 29
HDL (mg/dL) 58 ± 11 67 ± 21
Heart Rate (bpm) 65 ± 9 69 ± 17
SBP (mmHg) 111 ± 10 124 ± 6#
DBP (mmHg) 70 ± 8 78 ± 9*
MAP (mmHg) 84 ± 8 93 ± 6#
Values are means ± SD, n=10 per group. M, male; F, female; BMI, 
body mass index; LDL, low density lipoprotein; HDL, high density 
lipoprotein; SBP, systolic blood pressure; DBP, diastolic blood 
pressure; MAP, mean arterial pressure. *p<0.05 and #p<0.01 
compared with young.
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Table 2.2 
Baseline Cerebral Hemodynamics and Rebreathing Model Parameters 
 
 
 
 
 
 
 
 
 
 
Young Old
CBFV (cm/s) 72 ± 11 50 ± 14#
CVCi (cm/s/mmHg) 0.85 ± 0.13 0.55 ± 0.15#
CBFV-a 78 ± 27 83 ± 24
CBFV-b 0.55 ± 0.16 0.40 ± 0.12*
CBFV-x0 47 ± 3 48 ± 4
CBFV-y0 62 ± 24 73 ± 25
CBFV-CVMRmax 8.8± 1.7 7.8 ± 1.4
CVCi-a 58 ± 20 62 ± 20
CVCi-b 0.67 ±0.20 0.48 ± 0.14*
CVCi-x0 46 ± 2 47 ± 4
CVCi-y0 49 ± 21 55 ± 21
CVCi-CVMRmax 8.6 ± 2.2 6.9 ± 1.4*
Baseline CVMR Model Parameters
Values are means ± SD, n=10 per group. CBFV, cerebral blood 
flow velocity; CVCi, cerebral vascular conductance index; CVMR, 
cerebral vasomotor reactivity; a , range of change in CBFV or CVCi; 
b , curvilinear properties of the fitted curve; x0 , end-tidal CO2 value 
that exhibits highest slope; y0 , maximum value of CBFV or CVCi; 
CVMRmax, when CBFV or CVCi becomes maximal. *p<0.05 and 
#p<0.01 compared with young.
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Table 2.3 
Effect of Chronic Ingestion of Flavanols 
 
 
 
  
Baseline Placebo Flavanol
Sex, M/F 1/5
Age (yrs) 68 ± 3
BMI (kg/m2) 23.7 ± 2.7 23.1 ± 2.8 23.0 ± 2.8
Glucose (mg/dL) 88 ± 7 84 ± 4 82 ± 6
Total Cholesterol (mg/dL) 190 ± 20 186 ± 45 198 ± 29
Triglycerides (mg/dL) 61 ± 27 64 ± 20 65 ± 23
LDL (mg/dL) 102 ± 16 103 ± 30 111 ± 21
HDL (mg/dL) 77 ± 17 70 ± 20 75 ± 18
Heart Rate (bpm) 65 ± 7 67 ± 13 67 ± 15
SBP (mmHg) 131 ± 9 134 ± 8 124 ± 12
DBP (mmHg) 84 ± 8 82 ± 11 82 ±13
MAP (mmHg) 100 ± 8 99 ± 10 96 ± 12
Values are means ± SD, n=6. M, male; F, female; BMI, body mass index; 
LDL, low density lipoprotein; HDL, high density lipoprotein; SBP, systolic 
blood pressure; DBP, diastolic blood pressure; MAP, mean arterial pressure. 
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Figure 2.1 
 
 
 
 
  
Figure 2.1: A summary of the acute effects of treatment on CBFV and CVCi. Measurements 
were taken 2.5 hours following ingestion of either placebo or flavanol-containing test drink while 
subjects were breathing room air. Young and old individuals showed the same response. *p<0.05, 
#p<0.01 compared with pre in same treatment. Values are means ± SEM. 
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Figure 2.2  
 
 
 
  
Figure 2.2: A summary of the acute effects of treatment on cerebral reactivity in response to 
the rebreathing protocol. Reactivity was assessed 2.5 hours following ingestion of either placebo 
or flavanol-containing test drink. Young and old individuals showed the same response. *p<0.05 
compared with placebo pre, #p<0.01 compared with pre in same treatment. Values are means ± 
SEM. 
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Figure 2.3 
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Figure 2.3: A summary of the chronic effects of treatment on cerebral blood flow in older 
individuals. Measurements were taken after daily consumption of either a placebo or a flavanol-
containing test drink for 28 days. Subjects were breathing room air.*p<0.05 compared with 
baseline and the placebo. Values are means ± SEM. 
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Figure 2.4  
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Figure 2.4: Individual cerebral blood flow responses following the chronic ingestion 
of flavanols. All 6 subjects showed an increase in CVCi from baseline. Hollow 
squares represent individual pre & post values and filled-in squares represent means ± 
SEM. 
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Chapter VI:  Review of the Literature 
 
PATHOPHYSIOLOGY OF CVD 
The term CVD encompasses a number of different vascular diseases including 
hypertension, coronary heart disease, stroke, peripheral artery disease and diseases of the 
veins; all of which share a common underlying pathology, atherosclerosis. 
Atherosclerosis results from the complex interplay between structural elements of the 
arterial wall, circulating cells such as platelets & leukocytes, along with inflammatory 
cells such as monocytes/macrophages and can best be described, collectively, as an 
inflammatory disease (169). Central to this pathology is the vascular endothelium as it is 
the interface between blood and its elements and the underlying arterial wall. 
Histologically, there are 3 layers to the arterial wall and,  beginning from the lumen, they 
are as follows: 1) an intimal layer that is composed of a single layer of squamous 
epithelial cells and is termed the endothelium, 2) a medial layer that consists mainly of 
circumferentially arranged layers of smooth muscle cells contained within internal and 
external elastic membranes, and 3) an adventitial layer that is mainly composed of 
longitudinally arranged collagenous tissue that eventually merges with the loose 
connective tissue that surrounds the vessel. With regards to CVD our focus will be on the 
innermost layer, the endothelium. This layer was initially believed to serve primarily as a 
physical barrier separating blood and its contents from underlying tissue; however, it is 
now well understood that endothelial cells are crucial to vascular health in that they 
maintain vascular homeostasis by secreting a number of vasoactive mediators in response 
to a very dynamic environment. With regards to atherosclerosis, it is a disruption in the 
functioning of the endothelium that is the initiating pathology. 
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It is important to note that under normal circumstances the atherosclerotic process 
is protective in that it follows an insult to the endothelium and/or smooth muscle cells 
located in the layer below so that repair is possible. However, in instances of repeated 
vascular insult there is a chronic, excessive, inflammatory-fibro-proliferative response 
that has the potential to lead to an occlusive, atherosclerotic lesion. Several clear phases 
have been identified in the development of an atherosclerotic plaque (152, 170).  
1) Endothelial dysfunction: The primary event in the development of atherosclerosis is a 
disruption in endothelial function at an injury site. The most susceptible sites are areas 
near branch points in the arterial tree. Initial dysfunction results in the trapping of 
lipoproteins in the medial layer of the vessel wall and the expression of docking proteins 
on the endothelial cells apical membrane; changes that are under the influence of 
chemokines released by the altered endothelium and by other adherent leukocytes. Once 
these leukocytes have adhered to the docking proteins they then migrate between and 
across endothelial cells and gain access to the medial layer below.  
2) Inflammatory Phase: The leukocytes that have gained entry migrate further beneath 
the arterial surface and the monocytes transform into macrophages as a result of more 
locally-released mediators. The macrophages then accumulate lipid, become foam cells, 
and together with accompanying lymphocytes, present as a ‘fatty streak.’ There is 
evidence that oxidized low-density lipoprotein (oxLDL) is fundamental to the 
atherosclerotic process: it is able to directly cause injury to the endothelium, it plays a 
role in the initial adherence and migration of both monocytes and T-lymphocytes, it plays 
a role in the transformation of monocytes to macrophages, and its uptake by macrophages 
leads to foam cell formation and the fatty streak (129, 195). The fatty streak is the earliest 
recognizable lesion of atherosclerosis and the ubiquity of this atherosclerotic process is 
supported by the finding that fatty streaks exist in the coronary arteries of 65% of autopsy 
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specimens from children 12-14 years old (135, 190). Continued leukocyte influx and 
proliferation lead to more advanced fibrous lesions that are distinguished by multiple 
layers of foam cells and smooth muscle cells. 
3) Reparative Phase: The formation of fibrous lesions is a normal physiological response 
to injury; wound healing follows the same course. However, in atherosclerosis the cause 
of the injury, which is often lifestyle related, is most often chronic in nature. Chronic 
insult to this inflamed, focal site in the vessel by life style factors such as 
hypercholesterolemia, hypertension, smoking, obesity, and diabetes allows this process to 
propagate and become pathological. This persistent inflammatory condition has a number 
of deleterious vascular consequences. As smooth muscle cells lose their contractile 
properties and undergo change to a more fibroblastic phenotype, a fibrous cap forms over 
the injured area thereby providing some stability and this is collectively called plaque 
formation. However, though stable, potential consequences to this plaque formation 
include a thickening of the arterial wall, protrusion of the plaque into the arterial lumen 
where it can become restrictive to blood flow, and impaired diffusion of oxygen and 
nutrients to the tissue below.  
4) Thrombotic Phase: Atherosclerotic plaques vary significantly in their final 
composition, particularly in the thickness and stability of the fibrous cap. Those with a 
thick cap often remain stable over time and may present with no clinical consequence 
providing they do not protrude into the lumen of the vessel and restrict blood flow. 
However, those with a thin cap are vulnerable to rupture (fully or partially). A ruptured 
fibrous cap has 2 possible sequelae: 1) leads to the exposure of collagen from within the 
vessel wall to blood elements and 2) leads to the leakage of pro-thrombotic proteins from 
within the atherosclerotic lesion out into the bloodstream. Either or both of these can then 
activate the coagulation cascade as well as platelets, resulting in the formation of a 
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thrombus. It is either a restriction in blood flow or formation of a clot that account for the 
clinical sequelae of atherosclerosis including angina, claudication, myocardial infarction, 
and/or stroke.  
Endothelial dysfunction is the primary event in the pathology of atherosclerosis, a 
process that begins in childhood and continues throughout one’s lifetime. However, the 
risk factors associated with progression to clinical manifestations are often related to 
lifestyle choices and thus investigations into ways to preserve or restore endothelial 
function could significantly and positively alter the pathophysiology of CVD. 
 
ENDOTHELIAL FUNCTION AND THE ROLE OF NITRIC OXIDE 
 As previously stated, the endothelium is a major regulator of vascular homeostasis 
and does so by maintaining the balance between a number of physiological processes 
including: vasodilation vs. vasoconstriction, inhibition vs. stimulation of smooth muscle 
cell proliferation & leukocyte migration, and thrombogenesis vs. fibrinolysis. 
Accordingly, endothelial dysfunction results in an upset in one or all of these balances 
and is considered an early marker for atherosclerosis as it precedes angiographic or 
ultrasonic evidence of plaque formation (80).  
The Endothelium and Vasomotor Regulation: The maintenance of vascular tone comes 
from the ability of the endothelium to release a number of vasodilators and 
vasoconstrictors in response to signals from its environment (57, 120). Some of the more 
prevalent vasodilators include prostacyclin, bradykinin and endothelium-derived 
hyperpolarizing factor; however, the most significant vasodilator produced by the 
endothelium is nitric oxide (NO). Interplay and synergism among these vasodilators also 
contributes to an anti-atherogenic environment: inhibiting smooth muscle cell 
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proliferation and leukocyte migration and promoting fibrinolysis (120). The most 
important endothelium-derived vasoconstrictors are endothelin and angiotensin II. These 
vasoconstrictors contribute to a pro-atherogenic environment; they promote smooth 
muscle cell proliferation, leukocyte migration and thrombogenesis (120). Any disruption 
in the balance between these vasodilators and vasoconstrictors leads to a number of 
physiological consequences including increased endothelial permeability, platelet 
aggregation, leukocyte adhesion and generation of cytokines, all of these factors favor 
atherosclerotic plaque formation (as previously outlined).  
Functions of NO: NO was originally discovered and named endothelium-derived relaxing 
factor (73) before being specifically identified as NO (100, 148, 159). Since then, 
extensive research surrounding this molecule has demonstrated that NO is the primary 
paracrine involved in endothelium-dependent vasodilation. Along with this vasodilatory 
role, other functions of NO include inhibiting platelet adherence & aggregation, 
inhibiting leukocyte adhesions & infiltration, and inhibiting the proliferation of vascular 
smooth muscle cells (75, 111, 137). Furthermore, NO prevents the oxidative modification 
of LDL (171). As previously stated, oxLDL is believed to be one of the primary 
mechanisms underlying the atherosclerotic process and plasma concentrations of oxLDL 
have been shown to positively correlate with clinical manifestations of atherosclerosis 
(63). This suggests that NO bioavailability has the potential to directly modulate plasma 
levels of oxLDL. As a result of its inhibitory role, impaired production or reduced 
bioavailability of NO promotes events such as vasoconstriction, platelet aggregation, 
smooth muscle cell proliferation, and leukocyte adhesion with the deleterious 
consequence of atherosclerotic plaque formation and its associated clinical consequences.  
Production of NO: NO is formed by the reaction of nitric oxide synthase (NOS) on its 
substrate L-arginine thereby liberating both NO and L-citrulline (159). A number of 
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cofactors contribute to its production including tetrahydrobiopterin (BH4), nicotinamide 
adenine dinucleotide phosphate (NADPH), heme, flavin adenine dinucleotide (FAD), and 
flavin mononucleotide (FMN) (19). There are a number of constitutive isoforms of NOS 
including endothelial (eNOS), neuronal (nNOS), and inducible (iNOS). Our focus is on 
eNOS as it is the primary enzyme responsible for the generation of endothelial-derived 
NO (70). When inactive, eNOS is located within invaginations in the endothelial cell 
membrane termed caveolae where the protein caveolin-1 binds calmodulin (CaM), an 
essential allosteric activator of eNOS. Increases in intracellular Ca2+ activate CaM, which 
in turn dissociates from caveolin-1 and binds to eNOS, leading to its 
release/solubilization. Therefore, any increase in intracellular Ca2+ concentration via 
either transmembrane influx and/or release from intracellular storage sites activates 
eNOS and leads to the production of NO (19, 32, 186). Accordingly, activators of eNOS 
also include molecules such as bradykinin, acetylcholine, adenosine triphosphate (ATP) 
along with shear stress on the arterial wall.  
NO is a highly lipophilic and diffusible gas so it passes readily from the 
endothelial cell where it is produced to the smooth muscle cells in the medial layer 
below. Once in the smooth muscle cell, NO activates the enzyme guanylyl cyclase, which 
then converts GTP to cGMP, thereby inducing relaxation of the smooth muscle cell. Due 
to the short half-life of NO (3-5 seconds), tight temporal and spatial regulation of its 
production is essential. Several highly organized layers of regulation exist and the control 
of eNOS gene expression and post-translational modifications of the enzyme are crucial 
to this regulation. Phosphorylation of amino acid residues of eNOS appears to be one of 
the most important post-translational regulatory mechanisms and two of the most 
important sites appears to be the phosphorylation of Ser1177 and Thr495 (55, 149). The 
former of these enhances eNOS activity while the latter seems to be a major negative 
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regulatory site as it interferes with the bonding of CaM to eNOS (68, 132, 138). The 
critical role played by eNOS in vascular homeostasis is apparent in the fact that it is a 
highly regulated enzyme and its activity directly influences the production of NO; 
therefore, any bioactive molecule that has the potential to modulate the activity of eNOS 
also has the potential to effect vascular health. It is important to note that bioavailability 
of NO represents the balance between net production and usage. 
NO Bioavailability: The tight regulation of eNOS controls production of NO and then 
other factors have the potential to affect its bioavailability following production. Some of 
these factors include: excessive production of the superoxide anion (O2-), an increase in 
the intracellular concentration of the enzyme arginase and/or, an increase in ADMA.  
The presence of O2-, the one-electron reduction product of oxygen, provides an 
alternative pathway for NO as the two will react, in a nearly diffusion controlled reaction, 
to form peroxynitrite (NO + O2.- → ONOO-) (16). This reaction has two potentially 
harmful physiological consequences: the oxidization of cell components by peroxynitrite 
and a reduction in NO bioavailability (17). In this manner, production of O2- has the 
potential to modulate cellular, steady-state levels of NO. There are a variety of O2- 
sources in the body, but with reference to endothelial cells, NADPH oxidase (NOX) and 
eNOS dependent O2- production are particularly relevant (33). Oxidases are enzymes that 
catalyze oxidation reactions and under normal conditions, NOX generates O2- by 
catalyzing the transfer of electrons from NADPH to molecular oxygen (NADPH + 2O2 
↔ NADP+ + 2O2- + H+). There are a number of NOX isoforms that contribute to a 
variety of physiological functions including immunity, posttranslational processing of 
proteins, cellular signaling, regulation of gene expression and cell differentiation (18). 
However, the fact that NOX has a prominent role in vascular physiology is apparent in 
the observations that a moderate level of NOX is essential for optimal angiogenesis and 
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wound healing (205) but does become a risk factor for endothelial dysfunction when this 
level is exceeded (35). A second postulated source of excessive O2- production within the 
endothelial cell is eNOS. eNOS functions as a reductase enzyme as it catalyzes the 
flavin-mediated transfer of electrons from NADPH to a prosthetic heme group. This 
reaction requires BH4 as a cofactor in order to complete the electron transfer from the 
heme group to L-arginine thereby forming NO. In the absence of substrate or cofactor, 
eNOS becomes ‘uncoupled’ and produces O2- along with hydrogen peroxide instead 
(209). This has been supported by the observation that intra-arterial infusion of BH4 has 
been shown to improve endothelium-dependent vasodilation in chronic smokers, 
suggesting that depletion of BH4 may turn eNOS into an O2-·-generating enzyme in 
humans (91). The exact mechanisms whereby eNOS becomes uncoupled in vivo remains 
unclear; however, recent studies have suggested that peroxynitrite itself can oxidize BH4 
and lead to eNOS uncoupling (139). This brings forth the hypothesis that excessive 
production of O2- leads to an increased formation of peroxynitrite, which then oxidizes 
BH4 leading to the uncoupling of eNOS and further generation of O2-.   
An increase in the intracellular concentration of the enzyme arginase has also 
been implicated in reducing NO bioavailability. Arginase plays a role in NO 
bioavailability because it shares substrate with eNOS. In mammals, there are two 
isoforms of arginase, arginase I and II. Arginase I is a cytosolic enzyme, expressed 
primarily in the liver that is responsible for the conversion of L-arginine to urea and L-
ornithine thereby playing a role in ammonia detoxification. Arginase II is a mitochondrial 
enzyme, expressed primarily in the kidney, that plays a role in protein biosynthesis by 
supplying L-ornithine (216). Human endothelial cells express predominantly arginase II, 
which has been hypothesized to play a role in the endothelial dysfunction associated with 
atherosclerosis (11, 142). It has been shown that the availability of L-arginine can 
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represent a rate-limiting factor in cellular NO production in both animals and humans 
(47, 49, 58) thereby suggesting that an increase in arginase, and the resulting decrease in 
L-arginine, has the potential to indirectly reduce NO bioavailability. However, it is 
important to note that since these initial studies performed in the early 1990’s, further 
research has revealed inconsistent results suggesting that the link between arginase, 
eNOS and their common substrate, L-arginine, requires further investigation (119).  
An increase in asymmetric dimethylarginine (ADMA) has also been postulated to 
affect NO bioavailability as it is an endogenous competitive antagonist for the substrate, 
L-arginine (46). The production of NO is selectively inhibited by guanidine-substituted 
analogs of L-arginine, including L-NG-nitro arginine methyl ester (L-NAME), L-NG-
monomethyl-L-arginine (L-NMMA), and ADMA as they act as competitive inhibitors at 
the active site of the NOS enzyme (162). The first two of these analogues, L-NAME and 
L-NMMA, have been used extensively in vascular research and are often administered to 
ascertain the role of NO in a variety of research techniques that assess endothelial-
dependent vasodilation in an array of vessels. L-NMMA and ADMA occur endogenously 
as a result of the degradation of methylated proteins and following their formation they 
are either excreted without significant catabolism in urine (134) or they can be 
metabolized by the endothelium (122). Vallance et al. initially demonstrated that ADMA 
is present in a high enough concentration in plasma and urine to inhibit NOS in chronic 
renal failure patients and he suggested that it is the major endogenous NO inhibitor 
compared with L-NMMA (207). Since then, data from other studies demonstrate that 
ADMA may play a role in vascular pathology as it can elicit an inflammatory response in 
rats (113), it can inhibit vasodilation in rat & rabbit cerebral vessels that is prevented 
following the administration of L-arginine (65), and it can inhibit endothelium-dependent 
vasodilation via the inhibition of eNOS in human cerebral arteries (181). There is also 
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some evidence to suggest that ADMA is synthesized in human endothelial cells and is 
capable of uncoupling eNOS (9, 25) much the same as L-NMMA or LDL cholesterol 
(160). 
 One of the earliest signs of atherosclerosis, and an indicator of endothelial 
dysfunction, is decreased production and/or reduced bioavailability of NO hence NO 
plays a pivotal role in optimal functioning of the endothelium and in preserving vascular 
health over the lifetime. Excessive production of superoxide anion, increased levels of 
arginase, and/or increased ADMA have the potential to reduce NO bioavailability; 
therefore, any bioactive molecule that interferes with one or all of these factors have the 
potential to effect vascular health. 
 
FLAVANOLS AND VASCULAR HEALTH 
It is well established that diet plays a major role in the primary and secondary 
prevention of many chronic diseases, including those with impaired endothelial function 
as their underlying pathology. The endothelium constitutes the predominant tissue to 
which any molecule is exposed following digestion and absorption into the blood stream 
and thus represents a potential site of action for ingested compounds. Current dietary 
recommendations include the suggestion to consume more fruits and vegetables (98, 118) 
as there is significant evidence attesting to the negative association between their 
consumption and risk of CVD. It is now believed that much of this benefit comes from 
the polyphenols contained within these foods, of which flavonoids are a predominant 
group (6, 110). Numerous epidemiological and correlational studies have demonstrated 
the same inverse relationship between flavonoid ingestion and decreased risk of CVD 
(64, 143, 167). Initial in vitro experiments suggested that this negative association 
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between fruit and vegetable consumption and risk of vascular disease was due to the 
antioxidant capacity of these polyphenols (110). However, recent in vivo evidence 
suggests that a direct antioxidant action of flavonoids is unlikely since data from animal 
experiments and human interventional studies offer conflicting results (93). Though the 
underlying mechanism for their vascular benefit remains unclear, current evidence 
suggests they do exert their effects through the modulation of CVD risk factors: by 
improving endothelial function, inhibiting low-density lipoprotein oxidation, and/or by 
decreasing blood pressure as a result of their interaction with molecular signaling 
pathways and related machinery that regulates cellular processes (151). 
Flavonoids consist of a large family of phytochemicals that are present in a 
number of ‘healthy’ plant-derived foods.  These ‘bioactive’ compounds are extra-
nutritional constituents that typically occur in small quantities in foods and confer health 
benefit. All flavonoids contain the same 3-ring carbon skeleton and then the important 
subfamilies: flavanols (fruits, cocoa, tea and wine), flavonols (onion, broccoli, tomato, 
tea), flavones (herbs), isoflavones (soybean), flavanones (citrus fruits and juices), and 
anthocyanidins (berries and wine) differ based on which functional groups are attached to 
the ‘C-ring’ of this 3-ring carbon backbone. The arrangement and type of these attached 
chemical residues dictates how each of these different molecules will be absorbed and 
metabolized by the body following ingestion. During digestion, the process of 
conjugation occurs mainly in the small intestine and the liver and, in the case of 
flavonoids, leads to circulating metabolites that are mainly glucuronidated, sulphated 
and/or methylated so some of the resulting metabolites that reach the blood and tissues 
are chemically distinct from their parent compounds (64, 125). Accordingly, these 
different subfamilies give rise to different metabolic plasma profiles following digestion 
and; therefore, have differing physiological effects that determine their effects on health 
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(64, 126). It is important to note that there is no evidence for the long-term accumulation 
of these water-soluble metabolites, even when consumed in high doses. This rapid 
clearance implies that repeated and regular consumption of these foods is required to 
sustain plasma levels and derive vascular benefit. 
One of these flavonoid subfamilies, the flavanols, are defined by the presence of a 
hydroxyl group at position 3 of ring C and they are highly concentrated in foods such as 
fruits, red wine, green tea and cocoa products (154). Flavanols have received individual 
attention because they have demonstrated, independent of the others, to have cardio 
protective effects in epidemiological, observational and dietary intervention studies (7, 
31, 56, 105). In particular, research into the health benefits of cocoa were initiated by 
observations involving the Kuna Indians of Panama. These individuals reside on the 
island of San Blas, just off the coast of Panama, and they have a very low overall 
incidence of CVD and hypertension, positive health advantages that disappear when these 
island dwellers move to the mainland. A noteworthy difference between the Kuna Indians 
that remain on the island compared with those that move inland is their flavanol-rich 
cocoa consumption; cocoa is grown on the island and is one of the main beverages 
consumed by the island dwellers (15, 133, 180).  
Much the same as with flavonoids, studies involving flavanols have suggested 
that they work via the modulation of CV risk factors, including blood pressure (BP). The 
conclusions of a number of meta-analyses examining the effects of chocolate or cocoa on 
blood pressure have been that flavanol ingestion leads to a decrease in both diastolic and 
systolic blood pressure (164, 200). The underlying concept is that, sufficient NO 
bioavailability is associated with normal vasodilation and therefore normal BP; whereas, 
decreases in NO steady-state concentration can lead to a failure in smooth muscle 
relaxation and subsequent hypertension. A number of randomized, placebo-controlled 
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trials involving the ingestion of a flavanol-containing cocoa beverage have shown 
improvements in endothelial function; in conduit arteries as assessed by flow mediated 
dilation (FMD) (12, 87, 90, 147) and, in a smaller number of studies, in the 
microcirculation as assessed by peripheral arterial tonometry (PAT)(67, 180). These 
improvements in endothelial function were hypothesized to be the result of increased NO 
bioavailability as they were abolished by the inhibition of eNOS and/or plasma 
concentrations of flavanols and its metabolites were paralleled by an increase in plasma 
nitrosylated species (67, 90, 180).  
Though the specific profile of flavanols in the different food sources varies 
considerably and is dependent on food processing practices, they mostly exist as mixtures 
of the monomers, epicatechin (EP) and catechin (C), and the oligomers (procyanidins). 
Following digestion, the parent compounds EP and C can be found in plasma and urine 
along with a variety of their sulphated, methylated, and glucuronidated metabolites (10, 
153, 157, 158). The preponderance of evidence surrounding flavanols suggests that EP 
and its associated methylated metabolites are primarily responsible for the vascular 
benefits (12, 90, 161, 180, 193). Studies involving murine aortic endothelial cells have 
demonstrated that endothelial cells are capable of accumulating EP, possibly through 
binding to cellular proteins (179). This suggests that the concentration of EP that reaches 
the vascular endothelium after oral intake may be considerably higher than what is being 
measured in plasma and, under physiological conditions, protection by EP may outlast its 
presence in the plasma.  
The exact mechanism by which these molecules affect NO bioavailability has not 
yet been fully elucidated. Much the same as with their parent family, the  flavonoids, 
their beneficial effects were also initially believed to be due to their role as antioxidants, 
that they were able to scavenge free radicals that would otherwise react with NO and 
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reduce its bioavailability via the formation of peroxynitrite (as previously outlined). 
However, recent reviews and position papers are suggesting that the role of flavanols as 
antioxidants is actually minimal and their underlying mechanism may be via more 
indirect pathways. Hypothesized pathways include: by maintaining a high concentration 
of activated eNOS, by inhibiting NOX, and/or by decreasing arginase activity thereby 
preserving intracellular concentrations of L-arginine (71, 89, 177). 
Activation / Preservation of eNOS: The first of these postulated pathways is the role of 
flavanols in maintaining a high concentration of intracellular, activated eNOS thereby 
rendering it available for the production of NO. Ramirez-Sanchez et al. demonstrated in 
human coronary artery endothelial cells (HCAECs) that treatment with EP activates 
eNOS via phosphorylation of both Ser1177 and Ser633 along with the dephosphorylation of 
Thr495. These authors suggested that this provided evidence for the presence of a cell 
surface receptor for EP and could be a primary mediator in its cardiovascular effects 
(161). Steffen et al. demonstrated that exposure of endothelial cells to oxLDL caused 
proteasomal breakdown of the eNOS protein and this loss was prevented by a 16-hour 
pretreatment of the cells with EP. The eNOS protein was found to be particularly prone to 
protein carbonylation upon exposure to oxidative stress and the authors suggested that 
this carbonylation may serve as a signal for proteasomal degradation (192, 194). 
Inhibition of NOX: Another postulated pathway for the vascular benefits associated with 
flavanol ingestion is via inhibition of NOX, thereby leading to a reduction in O2- 
production. Aortas from rats treated with EP-containing, de-alcoholated, red wine 
demonstrated increased endothelial-dependent vasodilation and increased NO production 
along with a decreased superoxide production (20). Steffen et al. demonstrated that pure 
EP was associated with increased NO levels in human umbilical vein endothelial cells 
(HUVEC’s). These authors provided evidence that endothelial cells convert EP to its O-
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methylated metabolites and demonstrated these metabolites to be potent inhibitors of 
NOX. He concluded that this inhibition led to an elevation in the NO steady-state level in 
those endothelial cells. This conclusion was strengthened by the fact that the NO increase 
was prevented via inhibition of the enzyme catechol-O-methyltransferase, the enzyme 
responsible for the O-methylation of EP (193). These O-methylated metabolites have 
previously been reported in the plasma after flavanol ingestion by humans and rats and 
are structurally similar to apocynin, a well-known NOX inhibitor (191, 193).  
Inhibition of arginase: The final postulated indirect pathway for the vascular benefits 
associated with flavanol consumption involves the enzyme arginase. Schnorr et al. did a 
series of studies looking at the effects of flavanols on arginase in vitro and in vivo by 
using HUVEC’s, rat kidney and human erythrocytes. These authors demonstrated that 
there was a reduced arginase II mRNA expression in HUVECs following their incubation 
with EP and some of its common metabolites. This decrease was detectable in 2 hours but 
much more pronounced in 24 hours, and led to a detectable decrease in actual arginase II 
protein activity in those cells at 48 hours. Furthermore, these effects were dose-dependent 
and low levels of basal arginase 1 were unaffected. These same authors also 
demonstrated a decreased, renal arginase II activity in rats that had been fed a high 
flavanol diet for 28 days and a decreased arginase activity in human erythrocytes 24 
hours after the consumption of a high flavanol cocoa drink (178). The authors concluded 
that flavanols have the potential to indirectly influence NOS activity by increasing the 
availability of its substrate L-arginine. 
Acute vs. Chronic: There is evidence to suggest that the underlying mechanism 
accounting for the increase in NO bioavailability may differ between acute and chronic 
exposure to flavanols. This belief is supported by studies that demonstrate an increase in 
basal NO following long-term flavanol consumption that increases even further following 
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an acute dose of flavanols (12, 67, 88). Acute vascular effects are postulated to be 
mediated through the inhibition of NOX, whereas, chronic effects are believed to be 
mediated by maintaining a higher intracellular level of activated eNOS or by decreasing 
arginase activity within endothelial cell (177, 178). This longer term effect may be 
regarded as adaptation to continuous high-flavanol exposure and is possibly mediated by 
changes in gene expression and protein synthesis or breakdown (194). 
There is significant evidence to suggest that flavanols influence endothelial NO 
steady state levels. Investigation of their cellular actions will not only increase our 
understanding of the regulation of endothelial NO production but could provide valuable 
clues for prevention and/or treatment of CVD. 
 
AGING AND ENDOTHELIAL DYSFUNCTION 
Aging is associated with a progressive decline in basic physiologic function 
thereby leading to an increased risk of chronic diseases, including CVD, and their 
associated complications. However, age itself is not synonymous with disease as there are 
many people that achieve old age without evidence of disease, coined in the literature as 
‘successful aging.’ So the question becomes, what are possible explanations for this 
discrepancy and can interventions increase the number of individuals that fall into the 
latter category, that of successful aging? Some of the hypotheses put forth to explain the 
increased prevalence of CVD with age include: 1) risk factors associated with CVD 
increase in number and become more severe over time, 2) increasing age contributes to 
an increased exposure time to these same risk factors and/or, 3) CV structure and 
function change over time as a result of the aging process and this alters the substrate on 
which these same risk factors interact rendering individuals more susceptible to their 
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deleterious consequences. This latter hypothesis suggests that the increased incidence of 
CVD may be due to interactions between the vascular aging process and specific aspects 
of vascular disease pathophysiology; suggesting an age-disease interaction that increases 
in strength over time with both lifestyle related risk factors and genetics acting as 
contributors (114). Though there is considerable ongoing research into the contribution 
that genetics play in the pathology of CVD, our focus will be on the involvement of 
lifestyle risk factors, specifically diet. 
Aging of the CV system leads to a number of pathological changes in the 
vasculature that are believed to contribute to the atherosclerotic process. A sustained 
effort has been made over the past 2 decades to characterize the effects of aging on 
multiple aspects of CV structure and function in a single study population, the Baltimore 
Longitudinal Study on Aging (BLSA)(184). Results from the BLSA, along with other 
smaller-scale studies, have demonstrated that age-related structural vascular changes 
include: increases in luminal diameter, increased intimal media thickness (IMT), and 
increasing arterial stiffness along with impaired endothelial function (155). Our focus 
will be on impaired endothelial function as that is where, as outlined above, flavanols are 
believed to exert their positive vascular effects.  
It is well established that endothelium-dependent vasodilation, and therefore NO 
bioavailability, declines progressively with age. This has been supported by several 
studies involving rats that have demonstrated impaired endothelial function in both 
conduit and resistance vessels (76, 97, 112, 150). This same dysfunction has been 
demonstrated in numerous studies involving humans in conduit vessels such as the 
coronary arteries (62, 213, 217) and the brachial artery (121, 198) and also in resistance 
vessels (121, 187). However, many of these human studies examined only small numbers 
of subjects and/or subjects with multiple CVD risk factors. In a landmark study 
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investigating a much larger and apparently healthy cohort, Celermajer et al. demonstrated 
that aging is associated with progressive endothelial dysfunction in 238 volunteers from 
15 – 72 years of age with no known CVD risk factors. In addition, they demonstrated that 
endothelial dysfunction occurs earlier in men than woman, though it was present in 
almost all subjects by 65 years of age (39). All of these observations taken together 
suggest that this impairment in endothelial function is systemic in that it occurs in conduit 
and resistance vessels along with the microcirculation (2) and this is supported by 
evidence suggesting a reduction in overall, total body NO production with age (121). It is 
noteworthy that though atherosclerosis does not affect vessels of the microcirculation 
those vessels do demonstrate impaired endothelial function thus suggesting that this 
dysfunction may occur in the absence of atherosclerosis and/or may precede its 
development. Many of the aforementioned studies also demonstrated that endothelium-
independent relaxation to sodium nitroprusside remains unaffected by aging thereby 
suggesting that the impairment involves NO and does not involve the smooth muscle 
cells located in the medial layer below. 
There are a number of postulated mechanisms underlying this age-related 
reduction in the production and/or bioavailability of NO and they include: increased 
oxidative stress, reduced expression or activation of eNOS, upregulation of the enzyme 
arginase, and an increase in ADMA.  
Increased Oxidative Stress: It is well established that aging is associated with increased 
oxidative stress, the consequence of which is modification to cellular proteins, lipids and 
DNA. This results in an increased production of harmful metabolic byproducts such as 
reactive oxygen species (ROS), one of which is O2- (66, 82). Intracellular levels of ROS 
are tightly regulated because, under normal physiological conditions, they are important 
second messenger signaling molecules. However, it has been observed in human aortic 
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endothelial cells that excessive generation of ROS can result in unregulated inflammatory 
signaling, including the oxidation of circulating LDL and increased expression of 
inflammatory cytokines such as monocyte chemotactic protein-1 and vascular adhesion 
molecule-1 (74). In addition, as previously outlined, intracellular concentration of NO 
will decrease as a result of its reaction with O2- and the formation of peroxynitrite.  
There are a variety of postulated sources of the increased production of ROS with 
aging including: dysfunctional mitochondria (204, 215), the transformation of eNOS into 
a radical generating enzyme (115), and excess production by the enzyme NOX (28, 103). 
There is also evidence that the endothelium itself appears to be an important source of O2- 
in the vascular wall and the enzyme responsible is NOX (28, 79, 81, 103). This is further 
supported by the observation that the stimulation of dermal microvessel endothelial cells 
with angiotensin II, a potent inducer and activator of NOX, leads to DNA fragmentation 
(131).  
Reduced Expression and/or Activation of eNOS: At the molecular level, as endothelial 
cells age they exhibit a reduction in the expression of eNOS thereby reducing the 
production of NO and this has been demonstrated in both the aorta and in aortic 
endothelial cells from aged rats (14, 50, 199, 201) as well as in human endothelial cells 
(92, 128). Also, an age-induced loss of eNOS phosphorylation has been demonstrated in 
the aorta from aged rats (188, 189). eNOS expression is more dramatically reduced in 
areas such as the aorta, where there is significant hemodynamic stress compared with 
those areas that have a high endothelial cell concentration but experience less 
hemodynamic stress, such as the lungs (40). This pattern of reduced eNOS 
expression/activation and the resulting decrease in NO mimic the normal distribution of 
atherosclerosis. Numerous mechanisms can modulate eNOS activity but one of the most 
potent inducers for its transcription is hemodynamic shear stress, the frictional force 
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acting on the endothelial cell surface as a result of blood flow (45, 123, 124) as it 
increases eNOS mRNA expression and stability (54). As vessels age they are exposed to 
reduced shear stress as a result of the reduction in cardiac output that accompanies aging 
and this flow-induced reduction in NO has been demonstrated in rat coronary arterioles 
(104). Though response to shear stress is the primary stimuli, there are other factors that 
have been shown to affect the activity and expression of eNOS and they include: 
hormones such as estrogen (109), growth factors (27), and hydrogen peroxide(59). The 
secretion of many of these factors decreases with age so there is speculation that this 
decline may also affect eNOS expression and NO production. Studies have been done 
looking at the effects of the replacement of these factors on plaque formation and 
endothelial function in rats (5), rabbits (4, 78, 84), and humans (26) but results remain 
inconclusive.  
Upregulation of Arginase: Evidence suggests that NO bioavailability in aged skin may be 
decreased by an age-related upregulation of the enzyme arginase (61, 173). As previously 
stated increased levels of arginase reciprocally regulate NO bioavailability by pilfering 
substrate (21, 86, 214). The expression of arginase is increased with age in rabbits and in 
rats (172, 174) and inhibition of arginase in the aorta rings from aged rats improves 
endothelium-dependent relaxation (21). Furthermore, Holowatz et al. demonstrated that 
the age-related deficit in reflex cutaneous vasodilation in older humans can be restored by 
either arginase inhibition or L-arginine supplementation (95, 96).  
Increase in ADMA: ADMA is emerging as a novel CVD risk factor (23). Traditional risk 
factors account for the majority of risk for coronary events but there are certain 
individuals, lacking in these traditional risk factors, that still present with premature 
coronary artery disease suggesting that other, less defined, factors may also play a role. 
Increased ADMA levels are associated with reduced NO production in 
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hypercholesterolemic and in hypertensive patients, as judged by reduced urinary nitrate 
excretion and/or impaired endothelium-dependent, NO-mediated forearm vasodilation 
(24, 196). Studies involving both animal models and humans have suggested that an 
increase in ADMA occurs prior to vascular disease and it increases with aging. Miyazaki 
et al. assessed ADMA in the plasma of 116 apparently healthy human subjects, 26-77 
years old, who had no signs of vascular disease, and they found that ADMA levels were 
positively correlated with age (146). In another study by Valkonen et al. they showed that 
middle-aged men with ADMA plasma levels in the highest quartile had a 3.9-fold 
increased risk for acute coronary events compared with the other quartiles (206) 
suggesting that ADMA is a predictor of acute coronary events. Studies are suggesting 
that ADMA may only become damaging to the vasculature once its concentration 
exceeds some threshold, though a normal range has not been established.   
Flavanols exert their positive vascular benefits via some of the same postulated 
mechanisms that are accounting for the age-related reduction in NO bioavailability, 
thereby suggesting that the potential, positive health benefits that could be gained with 
habitual flavanol consumption may become more significant with age. Furthermore, 
ADMA has recently emerged as a novel CVD risk factor and it has been shown to be 
increased with aging so further investigation interaction with bioactive molecules may 
have the potential to guide future, more mechanistic studies.  
 
PHYSIOLOGICAL CONSEQUENCE TO REDUCED NO 
Impaired endothelial function is believed to be the result of decreased production 
and/or bioavailability of NO. As previously stated, in conjunction with its vasodilatory 
affects, NO also inhibits vascular inflammation, thrombotic events and aberrant cell 
 78
proliferation. Therefore, this age-related reduction in the physiological effects of NO 
greatly influences the vasculature as a whole; it affects vessels on a cellular level, 
mediating numerous changes in endothelial cell structure and function. As a result of its 
prominent role in normal vascular physiology, this decrease in NO results in detrimental 
physiological consequences, specific to the aging process, two of which include 1) 
increased oxidative stress and 2) induction of endothelial cell premature senescence. It is 
noteworthy to appreciate that there is some uncertainty as to whether or not increased 
oxidative stress and/or premature senescence are aging-associated or vascular disease-
associated phenomenon but it is becoming apparent that, regardless of their association, a 
reduced NO bioavailability is common to both. 
Increased Oxidative Stress: It was previously outlined that the increased oxidative stress 
associated with aging causes a reduction in NO bioavailability. However; a reduction in 
NO bioavailability by any mechanism also has the potential to increase oxidative stress as 
NO is no longer available to oxidatively inactivate (via the formation of peroxynitrite) 
newly formed radicals.  
Induction of Endothelial Cell Senescence: Though different processes such as endothelial 
injury, wound healing and/or angiogenesis can initiate endothelial cell proliferation, 
under normal conditions endothelial cells rarely divide, maybe every 3 years or so. As a 
result of their limited capacity for division, endothelial cells eventually enter a state of 
irreversible growth arrest, termed senescence (69). Evidence is suggesting that a 
reduction in NO may cause endothelial cells to enter premature senescence. During each 
normal cell division segments at the end of the chromosome, called telomeres, are lost as 
a result of limitations in the cell replication machinery. At some pre-defined telomere 
length the cell quits replicating; a defense mechanism against the loss of genes that code 
for relevant proteins. Normally, telomere shortening is minimized by the enzyme 
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telomerase as it functions to extend the end of the telomeres during each replication 
cycle. There is believed to be interaction between NO and telomerase such that NO 
activates telomerase thereby preventing the shortening of telomeres and, therefore, 
preventing premature exit from the cell cycle (208). The speculation is that endothelial 
dysfunction leads to a reduction in the bioavailability of NO, which then results in less 
protection by telomerase, accelerated shortening of telomeres and premature endothelial 
cell senescence. Senescent cells are metabolically active but display an altered gene and 
protein expression compared with proliferating cells. Specifically, they exhibit increased 
expression of inflammatory adhesion molecules and decreased NO production thereby 
perpetuating endothelial dysfunction and atherosclerosis (141). Endothelial cells 
displaying the senescent phenotype have been found localized at sites of atherosclerotic 
plaque formation (140) and this is further supported by the fact that the elderly display 
impaired wound healing and angiogenesis (166). 
 
ASSESSMENT OF ENDOTHELIAL FUNCTION 
As previously stated, the endothelium plays an integral role in maintaining 
vascular homeostasis and it is NO that mediates many of the protective functions exerted 
by a functioning endothelium. Thus, endothelium-dependent vasomotor function reflects 
the integrity of the endothelial layer and is often used as a surrogate of NO bioavailability 
in a variety of research and clinical methodologies. In both the clinical and research 
setting, endothelial function has been shown to be associated with atherosclerotic risk 
factors (176, 213) and is believed to be a predictor of adverse CV events (80, 197). 
Furthermore, evidence suggests that endothelial dysfunction is reversible with certain 
interventional strategies making its assessment even more relevant (36). The most 
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pertinent site to assess endothelial function in relation to CVD is the coronary arteries but 
that requires invasive techniques and is not practical for routine assessment. However, 
studies have shown a positive correlation between vasodilator impairment in the coronary 
circulation to that of the peripheral circulation (3, 175) suggesting that endothelial 
dysfunction is a systemic disorder allowing for it to be measured non-invasively at more 
accessible sites (2, 37). Endothelial dysfunction in the microcirculation is also established 
as an early marker of vascular disease; it predisposes to the development of 
atherosclerosis and it is also a systemic process that occurs in multiple tissue beds 
throughout the body (175, 210). Consequently, identification of impaired microvascular 
blood flow and vasoreactivity by noninvasive means can provide a quantitative 
assessment of the effects of a given intervention (1). 
The skin is emerging as an ideal site for evaluation of endothelial function and; 
furthermore, it has been suggested that the cutaneous microcirculation can serve as a 
model for generalized microvascular dysfunction (203). Additionally, changes in skin 
vascular reactivity are observed before clinical signs of microvascular dysfunction, 
during the early stages of many diseases, suggesting it precludes more globalized 
microvascular dysfunction (136). The cerebral circulation can also be used to assess 
endothelial function. Lavi et al. demonstrated that the chemoregulatory mechanisms of 
cerebral blood flow (CBF) are impaired in diseases affecting endothelial NO production 
and suggested that the CO2-NO axis is a primary pathway in the chemoregulation of CBF 
in humans (116). Furthermore, it has been demonstrated that acute systemic 
administration of L-arginine can restore cerebral reactivity in patients at CV risk (218).  
Thus, for these studies skin blood flow response to local heating (thermal 
reactivity; TR) and CBF response to hypercapnia (cerebral vasomotor reactivity; CVMR) 
were used as surrogates for NO bioavailability. These assessments allowed for the 
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investigation of the effects of flavanol ingestion on endothelial function in both the 
microvascular and cerebrovascular circulations. Skin blood flow response to a standard 
local heating protocol (TR) is a common, non-invasive research technique used to assess 
microvascular function and it has been shown to be predominantly NO-mediated (106, 
144). CBF response to hypercapnia (CVMR) has also been shown to be primarily NO-
mediated and, thus can be used as a surrogate of local cerebral endothelial function (117). 
Both TR and CVMR have been shown to be reduced with aging (13, 30, 145, 168); 
however whether or not endothelial function can be restored in these vascular beds 
following flavanol ingestion remains unknown.    
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Chapter VII: General Discussion and Future Directions 
These studies explored interactions between flavanols and nitric oxide (NO) in 
order to investigate implications for vascular health and cardiovascular disease (CVD). 
We chose to investigate endothelial function, as an indicator of NO bioavailability, in 2 
different vascular beds due to the systemic nature of CVD and to investigate the effect of 
flavanols in these different vascular beds. Study 1 investigated acute effects of flavanol 
consumption on cutaneous microvascular endothelial function in young and older 
individuals and explored the effects of chronic exposure in older individuals. This was 
accomplished by assessing skin blood flow response to local heating (thermal reactivity, 
TR); skin was clamped at 34°C and 40°C and values were normalized to those attained at 
43°C. The skin was chosen as it is emerging as an ideal site for evaluation of endothelial 
function and it has been suggested that the cutaneous microcirculation can serve as a 
model for generalized microvascular dysfunction (94, 108). Study 2 investigated the 
acute effects of flavanol consumption on cerebrovascular endothelial function in young 
and older individuals along with chronic flavanol exposure in older individuals. This was 
accomplished by assessing basal cerebral blood flow indices (cerebral vascular 
conductance index, CVCi) and CBF response to hypercapnia (cerebral vasomotor 
reactivity; CVMR). CVMR can be used as a surrogate of local cerebral endothelial 
function (117, 165), it has been shown to be predominantly NO-mediated (116) and has 
been shown to be reduced with aging (130, 168). 
There were a number of significant findings with study 1. Older individuals 
demonstrated a reduced TR at baseline compared with the young confirming an 
impairment in endothelial function as previous research has shown. There was an acute 
augmentation of SKBF response to local heating following flavanol ingestion; however, 
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it was not different between young and older individuals. Also, chronic exposure to 
flavanols had no effect on TR but did result in a significant decrease in blood pressure 
thereby still demonstrating vascular benefit.  
One of the goals of this study was to examine the acute effects of flavanol 
ingestion on the cutaneous vasodilator response to local heating and to determine if it 
differed in young versus older individuals. There was no effect of flavanols on TR in 
either young or older individuals when only the final, stable 5 minutes of the plateau 
phase during 40°C was considered, which is the most common data analysis protocol 
used to assess TR. An unexpected finding was that flavanols did lead to an acute, 
significant increase in the relative initial peak SKBF response to local heating at 40°C. 
The validity of this finding is strengthened by study design; the same effect was not seen 
following ingestion of the placebo only flavanols nor was it present during the initial 
peak response to 43°C. This effect was initially surprising because studies have shown 
that the initial peak response is primarily axon-mediated with less of a contribution from 
NO, whereas the plateau phase has a much greater contribution from NO (106, 144). 
Therefore, we had initially hypothesized that we would see the effect of flavanols in the 
latter phase. However, there is some contribution from NO over the entire local heating 
protocol as is evidenced by mechanistic studies that have shown a contribution of NO 
from 70-75% during the initial peak and 87-92% during the plateau phase and these same 
studies have shown the entire cutaneous vasodilatory response to be significantly blunted 
by the administration of L-NAME prior to local heating (60, 106, 144). Though this study 
was not mechanistic in design, we used a similar local heating protocol so we would 
surmise that a comparable relative contribution of NO was occurring during these studies. 
Consequently, we re-analyzed the data by averaging the entire SKBF response 
during the 30 minutes of 40°C local heating and normalizing it to the SKBF response 
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achieved during the last 5 minutes at 43°C. We hypothesized that we were detecting an 
effect of flavanols only during the initial peak because the overall response to local 
heating was less then than during the plateau phase so it represented a greater fractional 
change. This reasoning has been supported by a recent publication by Choi et al. that 
investigated different local heating protocols and concluded that a lower temperature 
resulted in less of a NO-mediated response and this may be more beneficial in 
interventional studies as it allowed for more room for interventions to ‘improve’ NO 
bioavailability by avoiding the potential ceiling effect (42). As we suspected, the 
significant effect of flavanols was not lost when the entire SKBF response to 30 minutes 
of 40°C local heating was considered. We believe the effect of flavanols was occurring 
not only during the initial peak, though it may have appeared more robust, but rather 
there was some effect on cutaneous vasodilatory response throughout the 30 minutes. In 
addition, the baseline impairment in TR between our young and older groups persisted 
with the re-analyzed data. 
This study was not mechanistic by design so we can only hypothesize as to the 
underlying cause of the increased NO bioavailability. A number of indirect pathways 
have been hypothesized for the effect of flavanols on NO bioavailability including: 1) 
interaction with endothelial nitric oxide synthase (eNOS) thereby maintaining it in an 
activated form, 2) by decreasing arginase activity leading to the preservation of 
intracellular concentration of L-arginine, and/or 3) by inhibiting NADPH oxidase (NOX) 
thereby limiting the generation of superoxide anions (71, 89, 177). eNOS has been shown 
to be the primary isoform responsible for the generation of NO during local heating; 
however its involvement in the initial peak SkBF response has been questioned (107, 
183). In this study it appears as though flavanols were exerting some effect over the 
entire phase of 40°C local heating, including the initial peak, suggesting it is less likely 
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that eNOS activation was the primary mechanism. Dupont et al. demonstrated that the 
plateau phase of heating at 40°C increased following the administration of both ascorbic 
acid and L-arginine whereas the initial peak response increased following the 
administration of ascorbic acid only (60). Free radicals, including the superoxide anion, 
lead to a reduction in NO bioavailability as they react with NO to form peroxynitrite (16, 
17). Flavanols have been shown to improve NO bioavailability via the inhibition of NOX 
(20, 191, 193), a major producer of superoxide anions in the endothelium (33). Similar to 
the effect of flavanols in this study, in the study by Dupont et al. the effects of ascorbic 
acid were seen during the initial peak along with the plateau suggesting the possibility 
that the effect of flavanols in this study may be due to NOX inhibition. Future, more 
mechanistic studies are required to elucidate underlying mechanisms.  
Contrary to our hypothesis, there was no significant age effect in this acute 
response to flavanol ingestion. However, as a result of the attenuation seen in the older 
individuals compared with the young at baseline, along with our initial hypothesis, and 
for discussion purposes we investigated the pair-wise comparisons to determine the 
magnitude of change in the young versus the older individuals. On both treatment days 
(placebo and flavanol), as expected, there was a significant decrease in TR in the older 
individuals compared with the young pre-ingestion of the test drink (p<0.05 for both). 
Following flavanol ingestion both the young and the older individuals increased, though 
the magnitude of the change was much greater in the older individuals (young: 58.1 ± 
3.0% to 60.0 ± 2.7%; older: 46.7 ± 3.1% to 52.5 ± 2.8%, p=0.07). There was no increase 
in either group following ingestion of the placebo (young: 59.6 ± 3.4% to 56.3±3.0%; 
older: 49.0 ± 3.5% to 49.1 ± 3.1%, p>0.05). This increase was significant when age 
groups were combined but did not quite reach significance as individual groups. We 
believe this may be related to subject recruitment. In order to limit confounders we 
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specifically recruited older individuals that were taking either no medication at all or very 
little and had not been diagnosed with CVD or any other metabolic illness. Not by 
coincidence, such individuals generally lead health conscious lifestyles and their diet and 
physical activity levels reflect this. Though none of the older individuals in the study 
were highly trained we believe they represented a healthier segment of the aging 
population and this could explain our lack of significance between our groups. We 
believe that future studies into the acute effects of flavanols on aging are warranted and 
should include more representative segments of our aging population. 
There was no significant difference in cutaneous vasodilatory response to local 
heating following chronic ingestion of flavanols in older individuals. There is the 
possibility that the quantity of flavanols provided or length of exposure time were not 
long enough to lead to cutaneous microvascular effects; however, this amount of time did 
result in a decrease in blood pressure. This provides evidence that, though there was no 
effect on TR, the quantity of flavanols and the length of time they were taken was 
sufficient to have a vascular effect. A number of meta-analyses have concluded that 
flavanols do have a blood pressure lowering effect and the results of this study support 
this previous research (164, 200). The underlying concept is that sufficient NO 
bioavailability is associated with normal vasodilation; whereas, decreases in NO steady-
state concentration can lead to a failure in smooth muscle relaxation and subsequent 
hypertension. With long term, at home interventions such as this compliance needs to be 
a consideration. However, in this study subjects complied with requests to return empty 
canisters and unused product and they were asked about compliance prior to each testing 
session so we do not believe that this played a role in the negative results.  
 There were also a number of significant findings with study 2. Once again, at 
baseline older individuals demonstrated a reduced CBF and a reduced cerebral reactivity 
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compared with the young supporting the premise of cerebral endothelial dysfunction in 
the older individuals. The consumption of flavanols led to an apparent acute decrease in 
both CBF and cerebral reactivity and this response was not different in the young versus 
the older individuals and yet chronic exposure led to an increase in CBF in older 
individuals but had no effect on cerebral reactivity.  
As has previously been demonstrated, older individuals had significantly lower 
CBFV and CVCi at baseline compared with younger individuals along with a decreased 
CVMR (13, 130, 163, 168, 202). It has been shown that NO contributes to baseline CBF 
tone and is also involved in CVMR (99, 102, 116) so this provides evidence for impaired 
cerebral endothelial function via a reduction in NO bioavailability in older individuals. 
Another significant difference at baseline was that the b model parameter was 
significantly lower in the older individuals compared with the young. The b model 
parameter is derived from the nonlinear logistic regression function that is used to assess 
CBFV response to hypercapnia and it represents the curvilinear properties of the resulting 
line of best fit. In response to hypercapnia, CBFV increases steadily along with PETCO2 
until it begins to level off at high levels of PETCO2 thereby generating a sigmoidal curve 
response. In this protocol, older individuals demonstrated a more linear response 
indicating they were less likely to plateau within the range of PETCO2 attained in this 
study. Claassen et al suggested 2 possible mechanisms for the plateau response to 
hypercapnia; there is a peak cerebral vasodilatory response to increasing PaCO2 or the 
vasoconstrictive effects of increasing sympathetic output are eventually overcoming 
vasodilation (44). Further investigation of the physiology associated with the b model 
parameter is required in order to determine if one of these hypothesized mechanisms is 
playing a role.  
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In this study, the curvilinear relationship resulting from the effects of hypercapnia 
on CBFV was analyzed using a four parameter logistic function as outlined by Claassen 
et al. as he suggests that this nonlinear curve fitting should be chosen over linear 
regression as it is a better model of the physiological response of CBFV (or CVCi) to 
hypercapnia (44). He suggests that there is added benefit to this method of analysis as it 
allows for the quantification of model parameters that may have physiological 
implications and should be considered when assessing CMVR: a the range in change of 
CBFV (or CVCi), y0 the maximum of CBFV (or CVCi) achieved during hypercapnia, x0 
the level of PETCO2 when the slope of the curve is maximal and b the curvilinear 
properties of the line. Additionally, the first order derivative of the logistic function used 
for the curve fitting generates a bell-shaped curve and the peak of that curve represents 
CBFV-CVMRmax (or CVCi-CVMRmax). In our experience further research is required 
regarding this type of analysis as there are some subjects, particularly those that do not 
plateau, that demonstrate model parameters (mainly y0 and a) that are outside of normal 
physiological range and this reduces their usefulness and suggests that caution is required 
when interpreting such data. We suggest that further studies are required to investigate 
the physiological implications of these model parameters in different subject populations 
to assess their usefulness in contributing to the information gained via CVMR. 
One of the goals of this study was to examine the acute effects of flavanol 
ingestion on cerebral vascular endothelial function and to determine if it differed in 
young versus older individuals. Contrary to our hypothesis was the finding that flavanol 
ingestion resulted in an acute, significant decrease in baseline CBFV and CVCi and that 
this response was the same in young and older individuals. Our hypothesis was that 
flavanols would cause vasodilation due to an increase in NO bioavailability; however, we 
hypothesized the vasodilatory response would be further downstream in the 
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microvasculature. In this study we used CBFV as a surrogate for CBF because we could 
not accurately measure MCA diameter. We made this assumption based on evidence 
from previous studies that have shown that MCA diameter does not change with 
perturbations such as changes in PaCO2 within the range used in this study (77, 182). 
However, the effect of flavanols on cerebral hemodynamics has not yet been investigated 
so the possibility exists that flavanols were causing vasodilation of the MCA. An increase 
in MCA diameter would provide a plausible explanation for these results but requires 
further investigation. Flavanols have been shown to have a vasodilatory affect on the 
brachial artery, also a conduit artery, in a number of studies (12, 87, 147).  
Also contrary to our hypothesis, there was a significant decrease in calculated 
CVMRmax acutely following flavanol ingestion and, again, this effect was not different 
between the young and older individuals. The R2 values ranged from 0.96 – 0.97 and 
were not different between treatments indicating that the fit to the nonlinear regression 
was not a factor in these results. In addition, the absolute range of PETCO2 that subjects 
experienced during their rebreathing protocol was not different between treatments 
indicating that their hypercapnic stimulus was equivalent. A more debatable finding was 
that the pre values on each of the treatment days were different; significantly higher on 
the day the flavanol-containing test drink was provided compared with the placebo. We 
believe that this decrease is CVMRmax remains significant based on the strength of the 
study design: 1) on each testing day post measures were assessed in relation to pre 
measures taken on the same day under the same conditions so this should account for any 
variability between the 2 intervention days and 2) this study was placebo-controlled and 
this same decrease from pre-ingestion was not seen following the ingestion of the 
placebo. This would suggest that flavanols were having an acute adverse effect as the 
general consensus is that endothelial dysfunction results in an attenuated CVMR. 
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However, we believe the acute decrease in calculated CVMRmax following flavanol 
ingestion may be due to differences in cerebral reactivity protocols and assessment 
techniques. We used a rebreathing protocol that assessed CBFV response to breath-by-
breath changes in PETCO2 and then chose a relatively novel four parameter logistic curve 
to assess CVMR as it was a better choice for the sigmoidal curvilinear response 
compared with linear regression. As a result, we believe that the decrease in calculated 
CVMRmax seen acutely following flavanol ingestion using this method of analysis 
requires further investigation to determine if it does indicate an impairment in 
cerebrovascular function. Other studies use stepped hypercapnia with or without a period 
of hypocapnia followed by linear regression to calculate CVMR (13, 116, 117, 211, 218). 
In this study, we chose not to include a hypocapnic stage as we were interested only in 
the vasodilatory effects of flavanols and our laboratory has previously shown that a prior 
hypocapnic stage has an effect on the subsequent vasodilatory response to hypercapnia 
(unpublished data). The preponderance of evidence regarding flavanols suggests a 
positive vascular benefit and further investigation is required to know if this benefit 
extends to the cerebral circulation.   
Older individuals demonstrated a significant increase in both CBFV and CVCi 
following 28 days of daily flavanol consumption. Though this is opposite the response 
seen acutely following flavanol ingestion it is not surprising as there is evidence to 
suggest that the underlying mechanism accounting for the increase in NO bioavailability 
differs between acute and chronic consumption of flavanols. This belief is supported by 
studies that demonstrate an increase in basal NO following long-term flavanol 
consumption that increases even further following an acute dose of flavanols (12, 67, 88). 
Acute vascular effects are postulated to be mediated through the inhibition of NADPH 
oxidase thereby limiting oxidative stress, whereas, chronic effects are believed to lead to 
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increased levels of activated eNOS or decreased arginase activity within endothelial cells 
(177, 178). The chronic effect is believed to be an adaptive response to continuous high-
flavanol exposure and therefore, mediated by changes in gene expression and protein 
synthesis or breakdown (194). As previously stated, NO contributes to tonic cerebral 
vascular tone so it is possible that this increase at baseline is due to an increase in basal 
NO having an effect on the cerebral microvasculature as hypothesized. Determination of 
which of the possible pathways is involved is outside the scope of the current study and 
requires further mechanistic investigation. There was no effect on any of the CVMR 
model parameters or calculated CVMRmax in older individuals following chronic 
exposure to flavanols. However, if the effect on NO bioavailability was not as robust as 
that seen with baseline CBFV and CVCi then there is a possibility that we did not detect 
it due to the small sample size.  
These studies explored interactions between aging, flavanols and NO in order to 
investigate implications for vascular health and cardiovascular disease (CVD) and they 
did so in two different vascular beds. Our main findings were that the ingestion of 
flavanols acutely improved cutaneous microvascular endothelial function in response to 
local heating but that this response was not different with aging and, though there was no 
effect on the cutaneous vasodilatory response to local heating following chronic exposure 
to flavanols, there was a beneficial vascular effect as was evidenced by a reduction in 
blood pressure. Our main finding with regards to cerebral endothelial function was that 
chronic exposure to flavanols resulted in a significant increase in baseline cerebral 
hemodynamics in older individuals but there was no effect on cerebral reactivity. The 
results from these studies contribute to current research by providing further support for 
vascular health benefits associated with flavanols. Further mechanistic studies are 
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warranted to elucidate underlying mechanisms as they could potentially guide future 
pharmacological research. 
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Appendix 
ACUTE STUDY INSTRUCTIONS 
Please follow these instructions before your next two visits (Study Days 1 & 2) to the 
laboratory where we will be assessing your vascular response to flavanol ingestion. 
 
Your scheduled study day is ______________ so please write down ALL of your food 
intake (see second page) from the day before, ________________ as you will be asked to 
consume a similar diet on the day prior to your next study day. In addition, we ask that 
you consume a low-flavanol diet in the 3 days prior to coming into the laboratory for 
testing. You will begin this diet on ________________________ and end it on 
________________________. Foods to avoid are listed below. 
 
PLEASE FOLLOW A FLAVANOL-POOR DIET IN THE 3 DAYS PRIOR TO 
YOUR STUDY DAY SO AVOID THE FOLLOWING FOODS AS THEY ARE 
FLAVANOL-RICH. 
 Chocolate and/or any cocoa products 
 Green/Fruit tea 
 Red wine 
 Fruits (or juice made from any of the following fruits) 
o Apples 
o Apricots 
o Bananas 
o Grapes 
o Nectarines 
o Peaches 
o Pears 
o Plums 
 Berries (blackberries, blueberries, raspberries, cherries, cranberries) 
 Nuts (pecans, pistachios) 
 Soybeans (anything made with soy) 
 Pinto Beans 
 Carob flour 
During the 24 hours before your testing session please do not engage in any strenuous 
physical activity and avoid alcoholic beverages. 
 
During the 12 hours before your testing session please do not eat or drink anything 
(water is ok). 
Your testing time is __________ so please do not eat after __________ the night before. 
Thank you; we appreciate our subjects and all that you do!!! 
 94
Subject ID# 
Dietary Log 
 
Please write down all of the food that you eat on the day prior to your scheduled visit to 
the laboratory. 
 
Breakfast: 
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
_____________________________________________________________ 
 
Midmorning Snack: 
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
___________________________________ 
 
Lunch: 
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
_____________________________________________________________ 
 
Afternoon Snack: 
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
_______________________________________ 
 
Supper: 
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
_____________________________________________________________ 
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CHRONIC INTERVENTION INSTRUCTIONS  
 
Please follow these instructions over the next 28 days that you consume your daily test 
beverage.  
 
To prepare daily test beverage: 
 Add 1 level scoop of powder to a cup, making sure NOT to pack the 
scoop. 
 Heat 8oz of water in microwave for about 1 minute (hot but not boiling). 
 Add hot water to powder in the cup, stir until ALL powder is dissolved. 
**Some people find it beneficial to mix the beverage into a container with 
a lid, for ease of mixing** 
 Drink entire beverage within 15 minutes. 
  
Please try to consume the beverage at approximately the same time each day (either in 
the morning, afternoon or evening). 
 
You will need to come in to the laboratory for your final testing day within 3 days of 
consuming your last test beverage. Your final scheduled study day is ______________. 
Your testing time is __________ so please do not eat after __________ the night before.  
 
During the 24 hours before your final testing session please do not engage in any 
strenuous physical activity and avoid alcoholic beverages. 
 
During the 12 hours before your testing session please do not eat (including 
supplements/vitamins) or drink anything (water is ok). 
 
 
Thank you; we appreciate our subjects and all that you do!!! 
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 TEST DRINK MIXING INSTRUCTIONS 
 
Below are the ‘test drink’ mixing instructions provided by The Hershey Company 
(product development branch). Instructions for mixing are the same for both the flavanol 
test drink and the placebo with the only difference being the size of the scoop (2 different 
size scoops were provided).  
 
To prepare the test drink: 
 Add 1 level scoop of powder to a cup, ensure that you do not pack the 
scoop. 
 Heat 8oz of water in microwave for about 1 minute (hot but not boiling). 
 Add hot water to powder in the cup, stir until ALL powder is dissolved. 
**You may choose to mix the beverage into a container with a lid so you 
can lightly shake it and ensure complete mixing** 
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